[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 8788
1. Wrzesień-Kuś A, Robak T, Wierzbowska A, Lech-Marańda E, Pluta A, Wawrzyniak E, Krawczyńska A, Kuliczkowski K, Mazur G, Kiebiński M, Dmoszyńska A, Wach M, Hellmann A, Baran W, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Polish Adult Leukemia Group: A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Ann Hematol; 2005 Sep;84(9):557-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
  • Purine nucleoside analogues, cladribine (2-chlorodeoxyadenosine, 2-CdA) and fludarabine (FAMP) are active agents in acute myeloid leukemias (AMLs).
  • Disease-free survival (1 year) was 68.6%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Cladribine / administration & dosage. Cytarabine / administration & dosage. Drug Therapy, Combination. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematologic Diseases / chemically induced. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Remission Induction / methods. Salvage Therapy / methods. Survival Analysis

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Factor II Deficiency.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15856358.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 47M74X9YT5 / Cladribine; BZ114NVM5P / Mitoxantrone; CLAG protocol
  •  go-up   go-down


2. Zhang YT, Luo ZF, Fang JP, Guo HX, Huang K, Li CK: [Detection of minimal residual disease in childhood acute lymphoblastic leukemia by using real-time quantitative PCR]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1235-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of minimal residual disease in childhood acute lymphoblastic leukemia by using real-time quantitative PCR].
  • This study was purposed to detect the minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) by using real time quantitative PCR (RQ-PCR) .

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129267.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


3. O'Malley DP, Orazi A, Wang M, Cheng L: Analysis of loss of heterozygosity and X chromosome inactivation in spleens with myeloproliferative disorders and acute myeloid leukemia. Mod Pathol; 2005 Dec;18(12):1562-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of loss of heterozygosity and X chromosome inactivation in spleens with myeloproliferative disorders and acute myeloid leukemia.
  • Neoplastic myeloid proliferations are seen in the spleens of some patients with acute and chronic myeloproliferative disorders.
  • Both acute myeloid leukemia (AML) and chronic myeloproliferative disorders have a variety of underlying cytogenetic defects that can be evaluated by loss of heterozygosity (LOH) studies.
  • A total of 17 spleens were evaluated (chronic myelogenous leukemia = 6; chronic idiopathic myelofibrosis = 6; essential thrombocythemia = 1; AML arising from previous chronic myeloproliferative disorders = 4).
  • We examined LOH loci 7q (D7S2554), 8q (D8S263), 9p (D9S157, D9S161), 13q (D13S319), common sites of genetic abnormality in chronic myeloproliferative disorders, and TP53.
  • [MeSH-major] Chromosomes, Human, X. Leukemia, Myeloid, Acute / genetics. Loss of Heterozygosity. Myeloproliferative Disorders / genetics. Spleen / pathology. X Chromosome Inactivation / genetics
  • [MeSH-minor] Bone Marrow Cells / pathology. Chronic Disease. Clone Cells. DNA, Neoplasm / analysis. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Microdissection. Polymerase Chain Reaction. Primary Myelofibrosis / genetics. Primary Myelofibrosis / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16118625.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


Advertisement
4. Uchiyama T: [Treatment of leukemia]. Nihon Naika Gakkai Zasshi; 2007 Mar 10;96(3):567-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of leukemia].
  • [MeSH-major] Leukemia / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Chronic Disease. Humans

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419429.001).
  • [ISSN] 0021-5384
  • [Journal-full-title] Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
  • [ISO-abbreviation] Nippon Naika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 5
  •  go-up   go-down


5. Hao WG, Huang SL, Sun X, Liu S: [Relationship between cellular immune function during conditioning and graft rejection in patients with beta-thalassemia major]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jul;29(7):1375-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyze the relationship between cell-mediated immune function during conditioning and graft rejection in patients with beta-thalassemia major.
  • METHODS: Allogeneic hematopoietic stem cell transplantation was performed in 25 children with beta-thalassemia major and 11 with acute leukemia group.
  • RESULTS: All the patients with acute leukemia showed engraftment.
  • In patients with beta-thalassemia major and graft rejection, the CD3(-)CD56(+) cell phenotype was predominant after conditioning but remained unchanged in those with engraftment.
  • CONCLUSION: CD3(-)CD56(+) NK cells are probably associated with graft rejection in patients with beta-thalassemia major, and may serve as an index for predicting graft rejection following allogeneic hematopoietic stem cell transplantation.
  • [MeSH-major] Graft Rejection / immunology. Graft vs Host Disease / immunology. Killer Cells, Natural / immunology. beta-Thalassemia / immunology
  • [MeSH-minor] Adolescent. Case-Control Studies. Child. Child, Preschool. Female. Hematopoietic Stem Cell Transplantation / adverse effects. Humans. Immunity, Cellular. Infant. Lymphocyte Count. Male

  • Genetic Alliance. consumer health - Thalassemia.
  • Genetic Alliance. consumer health - Beta Thalassemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620057.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] China
  •  go-up   go-down


6. Wang L, Lin D, Zhang X, Chen S, Wang M, Wang J: Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients. Leuk Res; 2005 Dec;29(12):1393-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients.
  • Genomic aberrations of Fms-like tyrosine kinase 3 (FLT3), including internal tandem duplication (ITD) and point mutations, have been demonstrated in 25-30% of adults acute myeloid leukemia (AML) and are markers of poor prognosis.
  • FLT3/ITD and D835 mutations were analyzed in 194 Chinese patients with acute leukemia and myelodysplastic syndromes (MDS) by polymerase chain reaction (PCR).
  • However, neither aberrations was found in 25 patients with acute lymphoblastic leukemia (ALL), 2 acute hybrid leukemia, 17 MDS and 7 chronic myeloid leukemia in blast crisis (CML-BC).
  • [MeSH-major] Leukemia / genetics. Mutation, Missense. Tandem Repeat Sequences. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Amino Acid Sequence. Asian Continental Ancestry Group / genetics. DNA Mutational Analysis. Female. Humans. Leukocytosis. Male. Middle Aged. Molecular Sequence Data. Myelodysplastic Syndromes / genetics. Prognosis. Remission Induction


7. Ladha AB, Courneya KS, Bell GJ, Field CJ, Grundy P: Effects of acute exercise on neutrophils in pediatric acute lymphoblastic leukemia survivors: a pilot study. J Pediatr Hematol Oncol; 2006 Oct;28(10):671-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of acute exercise on neutrophils in pediatric acute lymphoblastic leukemia survivors: a pilot study.
  • PURPOSE: This nonrandomized controlled trial was designed to investigate the effects of acute exercise on neutrophil count and function in children and adolescents receiving maintenance treatment for acute lymphoblastic leukemia (ALL) compared to matched controls.
  • [MeSH-major] Exercise. Neutrophils / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Survivors
  • [MeSH-minor] Acute Disease. Adolescent. Child. Exercise Test. Humans. Leukocyte Count. Male. Pilot Projects. Time Factors


8. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology: Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology; 2010 May 4;74(18):1463-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After a review of all the available evidence, the original report of the Therapeutics and Technology Assessment Subcommittee in 2003 concluded that mitoxantrone probably reduced clinical attack rates, MRI activity, and disease progression.
  • Subsequent reports of decreased systolic function, heart failure, and leukemia prompted the US Food and Drug Administration to institute a "black box" warning in 2005.
  • RESULTS: The accumulated Class III and IV evidence suggests an increased incidence of systolic dysfunction and therapy-related acute leukemia (TRAL) with mitoxantrone therapy.
  • Systolic dysfunction occurs in approximately 12% of patients with MS treated with mitoxantrone, congestive heart failure occurs in approximately 0.4%, and leukemia occurs in approximately 0.8%.
  • CONCLUSIONS: The risk of systolic dysfunction and leukemia in patients treated with mitoxantrone is higher than suggested at the time of the previous report, although comprehensive postmarketing surveillance data are lacking.

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • National Guideline Clearinghouse. treatment guidelines - National Guideline Clearinghouse .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mult Scler. 2002 Oct;8(5):441-5 [12356214.001]
  • [Cites] Neurology. 2002 Sep 24;59(6):954-5 [12297591.001]
  • [Cites] Mult Scler. 2003 Feb;9(1):59-62 [12617270.001]
  • [Cites] Mult Scler. 2003 Mar;9(2):213-4 [12708818.001]
  • [Cites] Leukemia. 2003 May;17(5):985-6 [12750718.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2123-37 [12775738.001]
  • [Cites] Mult Scler. 2003 Aug;9(4):426 [12926850.001]
  • [Cites] Neurology. 2003 Nov 25;61(10):1332-8 [14638950.001]
  • [Cites] Mult Scler. 2004 Feb;10(1):92 [14760961.001]
  • [Cites] J Neurol. 2004 Jun;251(6):762-3 [15311359.001]
  • [Cites] Leukemia. 1998 Mar;12(3):441-2 [9529141.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):233-55 [9748598.001]
  • [Cites] Intern Med J. 2005 Jul;35(7):382-7 [15958106.001]
  • [Cites] Eur Neurol. 2005;54(1):28-33 [16088176.001]
  • [Cites] Neurology. 2005 Sep 13;65(5):690-5 [16157900.001]
  • [Cites] J Neurol. 2005 Oct;252(10):1217-22 [15834643.001]
  • [Cites] Neurology. 2005 Dec 27;65(12):1997; author reply 1997 [16380636.001]
  • [Cites] Ann Neurol. 2006 Jan;59(1):206-9 [16374818.001]
  • [Cites] Arch Iran Med. 2006 Apr;9(2):111-4 [16649351.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2007 Feb;78(2):198-200 [17229751.001]
  • [Cites] Mult Scler. 2007 Jun;13(5):626-31 [17548442.001]
  • [Cites] Eur J Neurol. 2007 Nov;14(11):1281-7 [17956449.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):52-6 [17846110.001]
  • [Cites] Mult Scler. 2008 Mar;14(2):272-3 [17986509.001]
  • [Cites] Mult Scler. 2008 Jun;14(5):663-70 [18424479.001]
  • [Cites] Neurology. 2008 Aug 5;71(6):457-8 [18678830.001]
  • [Cites] Lancet. 2002 Dec 21-28;360(9350):2018-25 [12504397.001]
  • [Cites] Neurology. 2002 Sep 24;59(6):909-13 [12297576.001]
  • [CommentIn] Neurology. 2010 May 4;74(18):1410-1 [20439842.001]
  • (PMID = 20439849.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / 1 U01 NS 45719-01 A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cardiotoxins; BZ114NVM5P / Mitoxantrone
  • [Number-of-references] 40
  • [Other-IDs] NLM/ PMC2871006
  •  go-up   go-down


9. Lerch E, Espeli V, Zucca E, Leoncini L, Scali G, Mora O, Bordoni A, Cavalli F, Ghielmini M: Prognosis of acute myeloid leukemia in the general population: data from southern Switzerland. Tumori; 2009 May-Jun;95(3):303-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of acute myeloid leukemia in the general population: data from southern Switzerland.
  • AIMS AND BACKGROUND: To evaluate the outcome of adult patients with de novo acute myeloid leukemia in the Italian-speaking part of Switzerland and to identify prognostic factors, time to progression and overall survival.
  • METHODS AND STUDY DESIGN: Data of all adult patients diagnosed with acute myeloid leukemia from January 1984 to December 2003 were collected retrospectively.
  • RESULTS: The incidence of acute myeloid leukemia in the adult population in southern Switzerland is 2.6/100,000 per year.
  • In multivariate analysis (not including cytogenetic data), only age (P = 0.005), performance status > 1 (P = 0.001) and treatment given before/after 1993 (P = 0.044) were found to be independent prognostic factors for both overall survival and time to progression.
  • CONCLUSIONS: Most patients with acute myeloid leukemia are older than 60 years, and their outcome is still disappointing.
  • For younger patients, the prognosis is better if they receive high-dose cytarabine as post-remission therapy and if they are treated in the setting of a clinical trial.
  • [MeSH-major] Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Comorbidity. Cytarabine / administration & dosage. Disease Progression. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Odds Ratio. Palliative Care. Prognosis. Retrospective Studies. Switzerland / epidemiology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688968.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


10. Keefe JG, Sukov WR, Knudson RA, Nguyen LP, Williamson C, Sinnwell JP, Ketterling RP: Development of five dual-color, double-fusion fluorescence in situ hybridization assays for the detection of common MLL translocation partners. J Mol Diagn; 2010 Jul;12(4):441-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chromosomal rearrangements involving the mixed lineage leukemia (MLL) gene at 11q23 are frequent in adult and childhood acute leukemia and have been associated with an unfavorable prognosis.
  • A blinded study was performed for each probe set using 25 normal bone marrow samples, 25 t(4;11), 20 t(6;11), 20 t(9;11), 18 t(11;19p13.1), and 20 t(11;19p13.3) leukemia specimens as defined by chromosome analysis.
  • A normal cutoff of 0.6% was established, suggesting an application for these assays in minimal residual disease detection and disease monitoring.
  • [MeSH-major] Biological Assay / methods. In Situ Hybridization, Fluorescence / methods. Myeloid-Lymphoid Leukemia Protein / genetics. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1997 Dec 1;90(11):4532-8 [9373264.001]
  • [Cites] Leukemia. 1996 Aug;10(8):1283-7 [8709632.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Leukemia. 1999 May;13(5):679-86 [10374870.001]
  • [Cites] Leukemia. 2006 Feb;20(2):218-23 [16341046.001]
  • [Cites] Leukemia. 2006 Apr;20(4):620-6 [16437134.001]
  • [Cites] Leukemia. 2006 May;20(5):777-84 [16511515.001]
  • [Cites] Cancer Genet Cytogenet. 2007 May;175(1):8-18 [17498552.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):3000-6 [19380453.001]
  • [Cites] Haematologica. 2009 Jul;94(7):984-93 [19535349.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1490-9 [19262598.001]
  • [Cites] Blood. 2009 Sep 17;114(12):2489-96 [19528532.001]
  • [Cites] Br J Haematol. 2000 Apr;109(1):13-23 [10848777.001]
  • [Cites] Oncogene. 2001 May 24;20(23):2900-7 [11420702.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1714-20 [11535502.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5695-707 [11607819.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):41-7 [11731795.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2302-9 [11981001.001]
  • [Cites] Lancet. 2002 Jun 1;359(9321):1909-15 [12057554.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Leukemia. 2003 Apr;17(4):700-6 [12682627.001]
  • [Cites] Br J Haematol. 2003 May;121(4):566-77 [12752097.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Sep;145(2):144-51 [12935927.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2395-402 [12805060.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3093-6 [12842979.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Cancer Genet Cytogenet. 1988 May;32(1):59-66 [3281746.001]
  • [Cites] Cell. 1992 Nov 13;71(4):701-8 [1423625.001]
  • [Cites] Blood. 1993 May 1;81(9):2386-93 [8481519.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3705-11 [8260707.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):909-15 [8164041.001]
  • [Cites] Blood. 1995 Jun 1;85(11):3250-6 [7756657.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2870-7 [8639906.001]
  • [Cites] Br J Haematol. 1996 Jun;93(4):966-72 [8703835.001]
  • [Cites] Leukemia. 1998 May;12(5):840-4 [9593290.001]
  • (PMID = 20539022.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes; 0 / Nuclear Proteins; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  • [Other-IDs] NLM/ PMC2893628
  •  go-up   go-down


11. Brezinová J, Zemanová Z, Ransdorfová S, Pavlistová L, Babická L, Housková L, Melichercíková J, Sisková M, Cermák J, Michalová K: Structural aberrations of chromosome 7 revealed by a combination of molecular cytogenetic techniques in myeloid malignancies. Cancer Genet Cytogenet; 2007 Feb;173(1):10-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In bone marrow cells of 33 patients with myelodysplastic syndrome and acute myeloid leukemia, structural rearrangements of chromosome 7 were found with conventional G-banding: 8 with deletions 7q and 25 with translocations.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 7 / genetics. Leukemia, Myeloid / pathology. Myelodysplastic Syndromes / pathology
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Chromosome Banding. Chromosome Deletion. Cohort Studies. Female. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Karyotyping. Male. Middle Aged. Prognosis. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17284364.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Ferrara F, D'Arco AM, De Simone M, Mele G, Califano C, Pocali B, Danise P, Palmieri S: Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia. Haematologica; 2005 Jun;90(6):776-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.
  • BACKGROUND AND OBJECTIVES: A phase II study was conducted to investigate the effects of a therapeutic program based on the combination of fludarabine and cytarabine (ARA-C) administered as a sequential continuous infusion in untreated elderly patients with acute myeloid leukemia (AML).
  • DESIGN AND METHODS: Sixty-three patients with non-M3 AML, median age 69 years (range 61-81), were accrued.
  • Patients achieving complete remission (CR) were intended to receive an additional course, followed by autologous stem cell transplantation (ASCT).
  • The median overall and disease-free survival were both 10 months.
  • Results in terms of CR achievement, CD34+ cell collection and ASCT feasibility.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Aged. Aged, 80 and over. Antigens, CD34 / biosynthesis. Disease-Free Survival. Female. Humans. Male. Middle Aged. Myelodysplastic Syndromes / complications. Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951290.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD34; 04079A1RDZ / Cytarabine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


13. Pulte D, Gondos A, Brenner H: Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica; 2008 Apr;93(4):594-600
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century.
  • Treatment of adults with acute myeloblastic leukemia has changed substantially over the past two decades.
  • We estimated trends in age-specific 5- and 10-year relative survival of acute myeloblastic leukemia patients aged over 15 years old for 5-year calendar periods from 1980-1984 through 2000-2004 using data from the Surveillance, Epidemiology, and End Results Program.
  • Our period analysis reveals major improvement on the population level in long-term prognosis of younger patients with acute myeloblastic leukemia, most likely explained by multiple incremental improvements in care including better and more specific diagnosis, improvements in and extension of the use of stem cell transplantation and high dose therapy, and improved supportive care.
  • [MeSH-major] Leukemia, Myeloid, Acute / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Combined Modality Therapy. Disease Management. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Medical Oncology / methods. Medical Oncology / trends. Middle Aged. Mortality / trends. Prognosis. SEER Program / statistics & numerical data. Survival Analysis. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18322250.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Italy
  •  go-up   go-down


14. Karas Kuzelicki N, Milek M, Jazbec J, Mlinaric-Rascan I: 5,10-Methylenetetrahydrofolate reductase (MTHFR) low activity genotypes reduce the risk of relapse-related acute lymphoblastic leukemia (ALL). Leuk Res; 2009 Oct;33(10):1344-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5,10-Methylenetetrahydrofolate reductase (MTHFR) low activity genotypes reduce the risk of relapse-related acute lymphoblastic leukemia (ALL).
  • The reported correlation of defects in 5,10-methylenetetrahydrofolate reductase (MTHFR), the key enzyme of folate metabolism, with modulated risk for acute lymphoblastic leukemia (ALL) is ambiguous.
  • [MeSH-major] Methylenetetrahydrofolate Dehydrogenase (NAD+) / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Child. Child, Preschool. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Disease-Free Survival. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Genotype. Humans. Mutation. Recurrence. Reference Values. Retrospective Studies. Risk Factors. Slovenia

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178944.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 1.5.1.15 / Methylenetetrahydrofolate Dehydrogenase (NAD+)
  •  go-up   go-down


15. Palmieri S, Ferrara F, Leoni F, Ciolli S, Pollio F, D'Amico MR, Celentano M, Viola A, Vicari L, Izzo B, Pane F: Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype. Hematol Oncol; 2007 Mar;25(1):1-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype.
  • In this study, we analysed the prognostic relevance of foetal liver tyrosine kinase 3 (FLT3) mutations in 73 patients with acute myeloid leukaemia (AML) with normal karyotype, who survived induction and consolidation and received autologous stem cell transplantation (ASCT) after successful mobilization of peripheral blood stem cell (PBSC).
  • White blood cell count (p=0.009), serum concentration of lactate dehydrogenase (p=0.01), and percentages of peripheral blood (p=0.002) and bone marrow blasts (p=0.03) were significantly higher in patients showing the FLT3 mutations.
  • On the contrary, overall survival and disease-free survival were similar between patients with or without FLT3 mutations (p=0.73 and 0.78, respectively).
  • However, it is to consider that autografted patients are highly selected for best response to induction, consolidation and mobilization, as well as for minor non-haematologic toxicity.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid / diagnosis. Mutation. Myeloablative Agonists / therapeutic use. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Karyotyping. Male. Middle Aged. Prognosis. Remission Induction. Survival Analysis. Tandem Repeat Sequences. Transplantation, Autologous

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036374.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Myeloablative Agonists; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


16. Pui CH, Robison LL, Look AT: Acute lymphoblastic leukaemia. Lancet; 2008 Mar 22;371(9617):1030-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukaemia.
  • Acute lymphoblastic leukaemia, a malignant disorder of lymphoid progenitor cells, affects both children and adults, with peak prevalence between the ages of 2 and 5 years.
  • Steady progress in development of effective treatments has led to a cure rate of more than 80% in children, creating opportunities for innovative approaches that would preserve past gains in leukaemia-free survival while reducing the toxic side-effects of current intensive regimens.
  • Advances in our understanding of the pathobiology of acute lymphoblastic leukaemia, fuelled by emerging molecular technologies, suggest that drugs specifically targeting the genetic defects of leukaemic cells could revolutionise management of this disease.
  • Meanwhile, studies are underway to ascertain the precise events that take place in the genesis of acute lymphoblastic leukaemia, to enhance the clinical application of known risk factors and antileukaemic agents, and to identify treatment regimens that might boost the generally low cure rates in adults and subgroups of children with high-risk leukaemia.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18358930.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA68484; United States / NINR NIH HHS / NR / NR07610; United States / NCI NIH HHS / CA / CA36401; United States / NCI NIH HHS / CA / CA90246; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA78224; United States / NCI NIH HHS / CA / CA52259; United States / NCI NIH HHS / CA / CA60419; United States / NIGMS NIH HHS / GM / GM61393; United States / NCI NIH HHS / CA / CA06516; United States / NCI NIH HHS / CA / CA51001; United States / NCI NIH HHS / CA / P30 CA006516
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 171
  •  go-up   go-down


17. Thall PF, Estey EH, Markman M: Some ethical issues in phase II trials in acute leukemia. Clin Adv Hematol Oncol; 2006 Feb;4(2):95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Some ethical issues in phase II trials in acute leukemia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Clinical Trials, Phase II as Topic / ethics. Ethics, Research. Leukemia / drug therapy
  • [MeSH-minor] Acute Disease. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Clin Adv Hematol Oncol. 2005 Dec;3(12):943-8 [16555436.001]
  • (PMID = 16739255.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


18. Fang B, Song YP, Liao LM, Han Q, Zhao RC: Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells. Bone Marrow Transplant; 2006 Sep;38(5):389-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells.
  • [MeSH-major] Adipose Tissue / cytology. Graft vs Host Disease / therapy. Mesenchymal Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Female. Hematopoietic Stem Cell Transplantation / adverse effects. Humans. Immunosuppression / methods. Male. Pilot Projects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16878145.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


19. Costea I, Moghrabi A, Laverdiere C, Graziani A, Krajinovic M: Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica; 2006 Aug;91(8):1113-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia.
  • The gene polymorphisms of the methotrexate (MTX) action pathway influence event-free survival (EFS) in children with acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Folic Acid / metabolism. Folic Acid Antagonists / therapeutic use. Methotrexate / therapeutic use. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Child. Disease-Free Survival. Hematologic Diseases / chemically induced. Hematologic Diseases / epidemiology. Humans. Liver / drug effects. Liver / pathology. Polymorphism, Genetic


20. Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R, Ritz J, Antin JH, Soiffer RJ: Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant; 2006 Oct;12(10):1047-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
  • We reviewed 136 patients with advanced acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic transplantation to assess the impact of conditioning regimen intensity on outcome.
  • Thirty-nine patients receiving nonmyeloablative stem cell transplantation (NST) were compared with 97 patients receiving myeloablative transplantation.
  • These results demonstrate that dose intensity plays a significant role in control of disease after transplantation, but that this benefit is negated by increasing treatment-related mortality.
  • [MeSH-major] Bone Marrow Transplantation. Busulfan / administration & dosage. Cyclophosphamide / administration & dosage. Leukemia, Myeloid / surgery. Myelodysplastic Syndromes / surgery. Peripheral Blood Stem Cell Transplantation. Transplantation Conditioning. Vidarabine / analogs & derivatives. Whole-Body Irradiation
  • [MeSH-minor] Acute Disease. Adult. Aged. Female. Graft Survival. Graft vs Host Disease / epidemiology. Graft vs Host Disease / etiology. Humans. Incidence. Kaplan-Meier Estimate. Male. Middle Aged. Recurrence. Reoperation. Retrospective Studies. Tissue Donors. Transplantation, Homologous / mortality. Treatment Outcome


21. van de Loosdrecht AA, Westers TM, Westra AH, Dräger AM, van der Velden VH, Ossenkoppele GJ: Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood; 2008 Feb 1;111(3):1067-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients in progression to advanced MDS or acute myeloid leukemia had a significantly higher flow-score compared with non-transfusion-dependent patients.
  • In 60% of patients with transfusion dependency or progressive disease, myeloid blasts expressed CD7 or CD56, in contrast to only 9% of non-transfusion-dependent patients.
  • In addition, flow cytometry identified patients at risk for transfusion dependency and/or progressive disease independent of known risk groups, which might have impact on treatment decisions and the prognostic scoring system in the near future.
  • [MeSH-major] Flow Cytometry / methods. Myelodysplastic Syndromes / classification. Myelodysplastic Syndromes / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Neoplasm / immunology. Biomarkers, Tumor. Bone Marrow Cells / cytology. Cell Lineage. Disease Progression. Granulocytes / immunology. Humans. Immunophenotyping. Lymphoid Progenitor Cells / immunology. Middle Aged. Myeloid Progenitor Cells / immunology. Prognosis. Risk Factors. Sensitivity and Specificity. World Health Organization


22. Wang Q, Harrison JS, Uskokovic M, Kutner A, Studzinski GP: Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant. Leukemia; 2005 Oct;19(10):1812-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant.
  • Human myeloid leukemia cell lines are induced to terminal differentiation into monocyte lineage by 1,25-dihydroxyvitamin D3 (1,25D3) or its analogs (deltanoids).
  • We previously showed that either carnosic acid, an antioxidant, or SB202190, a p38 MAPK inhibitor, increase the potency of 1,25D3 in the HL60 cell line.
  • Here, we report that simultaneous addition of both these agents further increases differentiation potency of deltanoids in this cell line and in freshly obtained leukemic cells ex vivo.
  • Activity of MAPK pathways showed that increased differentiation was associated with enhanced activity of JNK pathway in all responding cell subtypes.
  • We conclude that the established cell line HL60 presents a good model for some, but not all, subtypes of myeloid leukemia, and that the JNK pathway plays an important role in monocytic differentiation of human leukemic cells ex vivo, as well as in vitro.
  • [MeSH-major] Antioxidants / therapeutic use. Cell Differentiation / drug effects. Enzyme Inhibitors / therapeutic use. Leukemia, Myeloid / drug therapy. Vitamin D / analogs & derivatives. p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Calcium / metabolism. Cell Lineage. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Monocytes / metabolism

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16107889.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Enzyme Inhibitors; 1406-16-2 / Vitamin D; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; SY7Q814VUP / Calcium
  •  go-up   go-down


23. Sirohi B, Powles R, Treleaven J, Kulkarni S, Saso R, Potter M, Ethell M, Morgan G, Singhal S, Mehta J: The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients. Bone Marrow Transplant; 2008 Jul;42(2):105-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients.
  • The 7-year probabilities of disease-free survival (DFS) and overall survival were 45 and 48%.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


24. Treuting PM, Albertson TM, Preston BD: Case series: acute tumor lysis syndrome in mutator mice with disseminated lymphoblastic lymphoma. Toxicol Pathol; 2010 Apr;38(3):476-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case series: acute tumor lysis syndrome in mutator mice with disseminated lymphoblastic lymphoma.
  • Acute tumor lysis syndrome (ATLS) is characterized by severe metabolic abnormalities and organ dysfunction resulting from rapid destruction of neoplastic cells.
  • Mice with ATLS had a high spontaneous mortality rate (>50%), a large tumor burden with disseminated disease, and evidence of leukemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Tumor Lysis Syndrome / pathology. Tumor Lysis Syndrome / veterinary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20190201.001).
  • [ISSN] 1533-1601
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / P01 AG01751; United States / NCI NIH HHS / CA / P01 CA77852; United States / NIEHS NIH HHS / ES / P30 ES07033; United States / NCI NIH HHS / CA / R01 CA098243; United States / NCI NIH HHS / CA / R01 CA111582; United States / NIEHS NIH HHS / ES / R01 ES09927; United States / NIEHS NIH HHS / ES / U01 ES11045
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Ramanarayanan J, Dunford LM, Baer MR, Sait SN, Lawrence W, McCarthy PL: Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients. Leuk Res; 2006 Jun;30(6):701-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.
  • Therapy-related myelodysplasia and acute myeloid leukemia are well described, but secondary chronic myeloid leukemia (CML) has only rarely been reported.
  • We report three patients with CML diagnosed 8, 10 and 2.5 years following Hodgkin's disease, non-Hodgkin's lymphoma and chronic lymphocytic leukemia therapy, respectively.
  • All three patients received imatinib therapy, with one patient subsequently undergoing allogeneic hematopoietic stem cell transplantation.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Neoplasms, Second Primary / therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Benzamides. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Remission Induction. Time Factors. Transplantation, Homologous


26. Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH, Sandlund JT, Rubnitz J, Ribeiro R, Campana D, Pui CH, Evans WE, Relling MV: Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood; 2005 Jun 15;105(12):4752-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.
  • Acquired genetic characteristics of acute lymphoblastic leukemia (ALL) cells are used to individualize therapy, whereas germ line genetic characteristics generally are not.
  • Of 246 children, 116 were treated on the lower-risk (LR) and 130 on the higher-risk (HR) arms of a St Jude protocol.
  • Patients in the HR group with the glutathione S-transferase (GSTM1) non-null genotype had greater risk of hematologic relapse (P = .03), which was further increased by the thymidylate synthetase (TYMS) 3/3 genotype (P = .03).
  • The GSTM1 non-null and TYMS 3/3 genotypes are plausibly linked to drug resistance.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827850847 for PMID:15713801 [PharmGKB] .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2002 Jun 1;359(9321):1909-15 [12057554.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1222-8 [10666194.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):813-23 [10673523.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1779-86 [11251009.001]
  • [Cites] Drug Metab Dispos. 2001 Apr;29(4 Pt 2):505-12 [11259341.001]
  • [Cites] Atherosclerosis. 2001 Jun;156(2):409-15 [11395038.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5505-10 [11454699.001]
  • [Cites] JAMA. 2001 Nov 14;286(18):2270-9 [11710893.001]
  • [Cites] Mol Pharmacol. 2001 Dec;60(6):1399-406 [11723248.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):802-10 [11895912.001]
  • [Cites] Blood. 2002 Jul 1;100(1):67-71 [12070010.001]
  • [Cites] Pharmacogenetics. 2002 Nov;12(8):605-11 [12439220.001]
  • [Cites] Leukemia. 2003 Jan;17(1):17-25 [12529655.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):529-37 [12571261.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):538-49 [12571262.001]
  • [Cites] Haematologica. 2003 Mar;88(3):353-4 [12651279.001]
  • [Cites] Drug Metab Dispos. 2003 May;31(5):589-95 [12695347.001]
  • [Cites] Blood. 2003 May 15;101(10):3862-7 [12531808.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3084-91 [12915598.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2001-7 [14559953.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2008-14 [14559954.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7369-75 [14576844.001]
  • [Cites] Blood. 2004 Jan 1;103(1):67-72 [12969965.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] N Engl J Med. 1986 Feb 20;314(8):471-7 [3456079.001]
  • [Cites] Lancet. 1990 Jul 28;336(8709):225-9 [1973780.001]
  • [Cites] Annu Rev Med. 1991;42:277-86 [2035973.001]
  • [Cites] Nature. 1994 Jan 20;367(6460):284-7 [8161378.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1383-9 [8021728.001]
  • [Cites] J Natl Cancer Inst. 1997 Feb 19;89(4):308-13 [9048835.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1701-7 [9057653.001]
  • [Cites] Ann Intern Med. 1997 Apr 15;126(8):608-14 [9103127.001]
  • [Cites] Mol Pharmacol. 1997 May;51(5):741-54 [9145912.001]
  • [Cites] N Engl J Med. 1997 Jul 10;337(2):77-82 [9211676.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jan;83(1):144-51 [9435432.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Blood. 1999 May 1;93(9):2817-23 [10216075.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1033-4 [11937185.001]
  • (PMID = 15713801.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / U01 1GM61374; United States / NCI NIH HHS / CA / CA 51001; United States / NCI NIH HHS / CA / CA 60419; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA 78224
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Calcitriol; EC 2.1.1.45 / Thymidylate Synthase; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  • [Other-IDs] NLM/ PMC1895006
  •  go-up   go-down


27. Matsunaga T, Murase K, Yoshida M, Fujimi A, Iyama S, Kuribayashi K, Sato T, Kogawa K, Hirayama Y, Sakamaki S, Kohda K, Niitsu Y: Donor cell derived acute myeloid leukemia after allogeneic cord blood transplantation in a patient with adult T-cell lymphoma. Am J Hematol; 2005 Aug;79(4):294-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor cell derived acute myeloid leukemia after allogeneic cord blood transplantation in a patient with adult T-cell lymphoma.
  • We report a patient with adult T-cell lymphoma who developed acute myeloid leukemia (AML) after allogeneic cord blood transplantation (CBT).
  • Although 25 cases of donor cell leukemia (DCL) occurring after allogeneic bone marrow transplantation have previously been reported, there have been no reports of DCL after CBT.
  • [MeSH-major] Cord Blood Stem Cell Transplantation. Leukemia, Myeloid / etiology. Lymphoma, T-Cell / therapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Acute Disease. Chromosomes, Human, X / genetics. Chromosomes, Human, Y / genetics. Fatal Outcome. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Tandem Repeat Sequences. Tissue Donors. Transplantation Chimera. Transplantation, Homologous


28. Chen CC, Weng HH, Hwang CE, Lu CH, Chen PT, Gau JP: Acute leukemia presenting with extramedullary diseases and completely normal hemogram: an extremely unusual manifestation unique to pre-B ALL. Am J Hematol; 2010 Sep;85(9):729-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukemia presenting with extramedullary diseases and completely normal hemogram: an extremely unusual manifestation unique to pre-B ALL.
  • Acute lymphoblastic leukemia (ALL) is a clonal hematological disease characterized by inadequate normal hematopoiesis secondary to excessive proliferation of leukemic blasts and their impaired differentiation.
  • Osteopathy involving multiple bones was noted initially, but acute leukemia was never considered as one of the differential diagnoses because of the completely normal hemogram in both cases.
  • Consequently, the diagnosis of leukemia was slightly delayed.
  • Upon literature review, we found that ALL patients with solely extramedullary diseases and nearly normal hemogram had exclusively pre-B disease.
  • [MeSH-major] Bone Neoplasms / diagnosis. Pain / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20687101.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


29. Hudson MM: Achieving cure for early stage pediatric Hodgkin disease with minimal morbidity: are we there yet? Pediatr Blood Cancer; 2006 Feb;46(2):122-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Achieving cure for early stage pediatric Hodgkin disease with minimal morbidity: are we there yet?
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Deoxycytidine / analogs & derivatives. Leukemia, Myeloid, Acute / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Recurrence. Treatment Failure

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Pediatr Blood Cancer. 2006 Feb;46(2):198-202 [16136581.001]
  • (PMID = 16261587.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


30. Girmenia C, Pagano L, Martino B, D'Antonio D, Fanci R, Specchia G, Melillo L, Buelli M, Pizzarelli G, Venditti M, Martino P, GIMEMA Infection Program: Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol; 2005 Apr;43(4):1818-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute myeloid leukemia accounted for 65.4% of the cases.
  • The incidence rates of Trichosporon sp. and G. capitatum infections in acute leukemia patients were 0.4 and 0.5%, respectively.
  • Death was reported for 57.1% of G. capitatum infections and for 64.7% of Trichosporon sp. infections.
  • A literature review on trichosporonosis in patients with any underlying disease or condition reveals G. capitatum as a predominantly European pathogen, particularly in certain Mediterranean areas, while Trichosporon sp. infections are seen with similar frequencies on all continents.
  • Well over half of these were suffering from acute leukemia (68 and 84% of patients with Trichosporon sp. and G. capitatum infections, respectively).

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 1989 Aug;160(2):356-7 [2760494.001]
  • [Cites] Rev Infect Dis. 1989 Nov-Dec;11 Suppl 7:S1591-9 [2532389.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1990 Mar;9(3):226-9 [2338090.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):484-7 [9452265.001]
  • [Cites] J Chemother. 1997 Dec;9(6):427-30 [9491843.001]
  • [Cites] Mycopathologia. 1997;139(1):15-8 [9511232.001]
  • [Cites] Mycoses. 1998 Mar-Apr;41(3-4):113-6 [9670762.001]
  • [Cites] J Clin Microbiol. 1998 Sep;36(9):2742-4 [9705427.001]
  • [Cites] J Clin Microbiol. 1998 Oct;36(10):2950-6 [9738049.001]
  • [Cites] Ann Dermatol Venereol. 1998 Feb;125(2):111-3 [9747226.001]
  • [Cites] Rev Med Interne. 1998 Jun;19(6):431-3 [9775185.001]
  • [Cites] J Rheumatol. 1998 Nov;25(11):2276-8 [9818677.001]
  • [Cites] Antonie Van Leeuwenhoek. 1998 Nov;74(4):229-35 [10081582.001]
  • [Cites] J Clin Microbiol. 1999 Jun;37(6):1985-93 [10325360.001]
  • [Cites] Clin Infect Dis. 1999 May;28(5):1071-9 [10452637.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Apr;46(4):1144-6 [11897610.001]
  • [Cites] Ann Hematol. 1994 Mar;68(3):159-61 [8167183.001]
  • [Cites] Mycoses. 1999;42(9-10):543-8 [10592698.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Jan;44(1):57-62 [10602723.001]
  • [Cites] J Formos Med Assoc. 1999 Nov;98(11):787-9 [10705698.001]
  • [Cites] Bone Marrow Transplant. 2000 Apr;25(7):745-9 [10745260.001]
  • [Cites] J Am Acad Dermatol. 2000 May;42(5 Pt 2):929-31 [10767708.001]
  • [Cites] Br J Haematol. 2001 Jul;114(1):93-8 [11472350.001]
  • [Cites] Clin Infect Dis. 2001 Sep 1;33(5):E28-30 [11477533.001]
  • [Cites] J Korean Med Sci. 2001 Aug;16(4):505-8 [11511798.001]
  • [Cites] Clin Infect Dis. 2002 Jan 1;34(1):7-14 [11731939.001]
  • [Cites] J Clin Microbiol. 2001 Dec;39(12):4420-5 [11724855.001]
  • [Cites] Mycoses. 2001 Dec;44(11-12):505-12 [11820266.001]
  • [Cites] Pediatr Infect Dis J. 2002 Feb;21(2):169-70 [11840088.001]
  • [Cites] Med Mycol. 2002 Feb;40(1):83-6 [11862981.001]
  • [Cites] Mycoses. 2002 Apr;45(3-4):123-5 [12000516.001]
  • [Cites] Clin Infect Dis. 2002 Jul 15;35(2):e22-5 [12087540.001]
  • [Cites] Diagn Microbiol Infect Dis. 2002 Jun;43(2):167-70 [12088626.001]
  • [Cites] Clin Infect Dis. 2002 Aug 1;35(3):E35-6 [12115115.001]
  • [Cites] Diagn Microbiol Infect Dis. 2002 Sep;44(1):17-22 [12376026.001]
  • [Cites] J Clin Microbiol. 2003 Jan;41(1):479-82 [12517900.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2002 Dec;21(12):892-6 [12525928.001]
  • [Cites] Clin Exp Dermatol. 2003 Jan;28(1):37-8 [12558627.001]
  • [Cites] Clin Infect Dis. 2003 Feb 15;36(4):E63-6 [12567323.001]
  • [Cites] J Clin Microbiol. 2003 Feb;41(2):911 [12574315.001]
  • [Cites] J Allergy Clin Immunol. 2003 Jun;111(6):1370-4 [12789241.001]
  • [Cites] Mycoses. 2003 Sep;46(8):293-8 [12950897.001]
  • [Cites] J Chemother. 2003 Aug;15(4):412-3 [12962373.001]
  • [Cites] Am J Perinatol. 2003 Jul;20(5):269-71 [13680511.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2003 Nov;37(5):620-3 [14581808.001]
  • [Cites] J Clin Microbiol. 2003 Nov;41(11):5317-20 [14605194.001]
  • [Cites] Pediatr Infect Dis J. 2003 Nov;22(11):1022-4 [14628778.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Dec;47(12):3985-8 [14638517.001]
  • [Cites] J Clin Microbiol. 2003 Dec;41(12):5623-32 [14662952.001]
  • [Cites] J Clin Microbiol. 2003 Dec;41(12):5827-9 [14662994.001]
  • [Cites] Clin Infect Dis. 2004 Feb 1;38(3):335-41 [14727202.001]
  • [Cites] Br J Haematol. 2004 Feb;124(4):405 [14984489.001]
  • [Cites] J Clin Microbiol. 2004 Apr;42(4):1832-6 [15071063.001]
  • [Cites] Int J Syst Evol Microbiol. 2004 May;54(Pt 3):995-8 [15143054.001]
  • [Cites] Zentralbl Bakteriol Orig. 1965 Apr;196(1):121-33 [5854508.001]
  • [Cites] J Med Microbiol. 1970 Feb;3(1):191-3 [5448879.001]
  • [Cites] J Clin Pathol. 1981 Mar;34(3):267-70 [6939693.001]
  • [Cites] J Infect Dis. 1983 Feb;147(2):199-203 [6827136.001]
  • [Cites] J Infect. 1983 Mar;6(2):183-5 [6576066.001]
  • [Cites] Lancet. 1985 Jul 6;2(8445):43-4 [2861489.001]
  • [Cites] Medicine (Baltimore). 1986 Jul;65(4):268-79 [3523114.001]
  • [Cites] Rev Infect Dis. 1986 Nov-Dec;8(6):959-67 [3541129.001]
  • [Cites] J Clin Microbiol. 1987 Jul;25(7):1191-4 [3611311.001]
  • [Cites] Ann Intern Med. 1988 May;108(5):772-3 [3358587.001]
  • [Cites] Bone Marrow Transplant. 1987 Oct;2(3):321-7 [3332179.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Apr;15(4):432-4 [2925989.001]
  • [Cites] Am J Clin Pathol. 1989 Jul;92(1):119-23 [2665472.001]
  • [Cites] Jpn J Med. 1991 Mar-Apr;30(2):135-7 [1865584.001]
  • [Cites] Rev Infect Dis. 1991 May-Jun;13(3):487-92 [1866554.001]
  • [Cites] Br J Neurosurg. 1991;5(5):515-7 [1764234.001]
  • [Cites] Clin Infect Dis. 1992 Mar;14 Suppl 1:S43-53 [1562695.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1991 Sep;10(9):752-6 [1810730.001]
  • [Cites] J Infect Dis. 1992 Jul;166(1):121-33 [1535092.001]
  • [Cites] Scand J Infect Dis. 1992;24(2):245-7 [1641603.001]
  • [Cites] Antonie Van Leeuwenhoek. 1992 May;61(4):285-8 [1497333.001]
  • [Cites] Clin Exp Dermatol. 1992 Mar;17(2):79-82 [1516247.001]
  • [Cites] Burns. 2000 Aug;26(5):483-6 [10812273.001]
  • [Cites] Leuk Lymphoma. 2000 Sep;39(1-2):209-12 [10975401.001]
  • [Cites] Clin Infect Dis. 2000 Aug;31(2):621 [10987737.001]
  • [Cites] Pediatr Infect Dis J. 2000 Oct;19(10):1025-7 [11055614.001]
  • [Cites] Enferm Infecc Microbiol Clin. 2000 Jun-Jul;18(6):291-2 [11075489.001]
  • [Cites] Clin Infect Dis. 2000 Sep;31(3):822-4 [11017841.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2001 Feb;20(2):139-42 [11305471.001]
  • [Cites] Diagn Microbiol Infect Dis. 2001 Mar;39(3):161-4 [11337182.001]
  • [Cites] Transplant Proc. 2000 Nov;32(7):2392-5 [11120213.001]
  • [Cites] Nephrol Dial Transplant. 1999 Aug;14(8):2017-8 [10462290.001]
  • [Cites] Eur J Dermatol. 1999 Oct-Nov;9(7):577-9 [10523742.001]
  • [Cites] Am J Clin Pathol. 1982 Nov;78(5):792-4 [6890308.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2793-5 [2340472.001]
  • [Cites] Pediatr Infect Dis J. 1990 Jul;9(7):520-2 [2196517.001]
  • [Cites] J Clin Microbiol. 1990 Jul;28(7):1616-22 [2380383.001]
  • [Cites] Pathol Biol (Paris). 1990 Jun;38(5 ( Pt 2)):585-8 [2385456.001]
  • [Cites] Rev Infect Dis. 1990 Jul-Aug;12(4):570-82 [2385764.001]
  • [Cites] Bone Marrow Transplant. 1990 Sep;6(3):219-21 [2252963.001]
  • [Cites] J Chemother. 1991 Feb;3(1):13-5 [2019857.001]
  • [Cites] Kansenshogaku Zasshi. 1992 Aug;66(8):1129-32 [1402121.001]
  • [Cites] Clin Infect Dis. 1992 Nov;15(5):781-7 [1445976.001]
  • [Cites] AIDS. 1993 Jan;7(1):139-40 [8442911.001]
  • [Cites] Haematologica. 1993 Jan-Feb;78(1):64-7 [8098313.001]
  • [Cites] Arch Dermatol. 1993 Aug;129(8):1020-3 [8352606.001]
  • [Cites] Kansenshogaku Zasshi. 1993 Aug;67(8):704-11 [8409577.001]
  • [Cites] J Clin Microbiol. 1994 Jan;32(1):224-7 [8126186.001]
  • [Cites] J R Soc Med. 1994 May;87(5):292-3 [8207729.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1994 Mar;13(3):218-24 [8050434.001]
  • [Cites] Mycoses. 1994 Jan-Feb;37(1-2):3-10 [7935589.001]
  • [Cites] Clin Infect Dis. 1994 Aug;19 Suppl 1:S8-13 [7948573.001]
  • [Cites] Rev Inst Med Trop Sao Paulo. 1994 Mar-Apr;36(2):121-3 [7997786.001]
  • [Cites] Burns. 1994 Oct;20(5):467-8 [7999281.001]
  • [Cites] Infection. 1994 Jul-Aug;22(4):283-6 [7528173.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1994 Jul;13(7):604-6 [7805691.001]
  • [Cites] Antimicrob Agents Chemother. 1994 Nov;38(11):2541-4 [7872744.001]
  • [Cites] Acta Derm Venereol. 1994 Nov;74(6):481-2 [7701893.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1995 Feb;14(2):148-9 [7758485.001]
  • [Cites] Clin Infect Dis. 1995 Apr;20(4):913-6 [7795094.001]
  • [Cites] Chest. 1995 Jul;108(1):190-5 [7606957.001]
  • [Cites] J Formos Med Assoc. 1995 Mar;94(3):127-31 [7613244.001]
  • [Cites] J Clin Microbiol. 1995 May;33(5):1368-70 [7615757.001]
  • [Cites] Mycoses. 1995 Mar-Apr;38(3-4):125-6 [7477087.001]
  • [Cites] Ann Hematol. 1996 Jul;73(1):33-4 [8695721.001]
  • [Cites] Infection. 1996 May-Jun;24(3):273-4 [8811374.001]
  • [Cites] Support Care Cancer. 1996 Jul;4(4):291-3 [8829307.001]
  • [Cites] Clin Infect Dis. 1996 Aug;23(2):396-7 [8842284.001]
  • [Cites] J Infect. 1996 Jan;32(1):70-1 [8852557.001]
  • [Cites] Haematologica. 1996 Jul-Aug;81(4):352-5 [8870383.001]
  • [Cites] J Clin Microbiol. 1996 Mar;34(3):753-5 [8904454.001]
  • [Cites] Mycoses. 1996 May-Jun;39(5-6):195-9 [8909029.001]
  • [Cites] Antimicrob Agents Chemother. 1997 May;41(5):1156-7 [9145888.001]
  • [Cites] Harefuah. 1997 Mar 16;132(6):396-8, 448, 447 [9153853.001]
  • [Cites] Blood. 1997 Aug 1;90(3):999-1008 [9242529.001]
  • [Cites] Am J Perinatol. 1997 Feb;14(2):113-7 [9259910.001]
  • [Cites] J Clin Microbiol. 1998 Jan;36(1):198-202 [9431946.001]
  • (PMID = 15815003.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 396
  • [Other-IDs] NLM/ PMC1081342
  •  go-up   go-down


31. Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N: The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer; 2006 Jan 1;106(1):112-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
  • BACKGROUND: Valproic acid (VPA) inhibits histone deacetylase activity and, synergizing with all-trans retinoic acid (ATRA), achieves differentiation induction of myeloid blast cells in vitro.
  • METHODS: We used VPA in 58 patients with acute myeloid leukemia (AML) who were too old and/or medically unfit to receive intensive chemotherapy (32 AML secondary to myelodysplastic syndrome [MDS], 22 de novo AML, 4 AML secondary to myeloproliferative syndrome).
  • RESULTS: The response rate was only 5% according to International Working Group (IWG) criteria for AML but was 16% when IWG response criteria for MDS were used, which capture hematologic improvement and stabilization of the disease.
  • These endpoints, which are not necessarily correlated with diminishing blast counts, are relevant for the patients' quality of life.
  • Among 23 patients with a peripheral blast count > 5%, 6 (26%) showed a diminishing blast count, and 5 of these had a complete peripheral blast clearance.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Histone Deacetylase Inhibitors. Leukemia, Myeloid / drug therapy. Tretinoin / therapeutic use. Valproic Acid / therapeutic use
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Treatment Outcome


32. Cilloni D, Messa F, Arruga F, Defilippi I, Gottardi E, Fava M, Carturan S, Catalano R, Bracco E, Messa E, Nicoli P, Diverio D, Sanz MA, Martinelli G, Lo-Coco F, Saglio G: Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica; 2008 Jun;93(6):921-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy.
  • The Wilms' tumor gene WT1 is a reliable marker for minimal residual disease assessment in acute leukemia patients.
  • The study was designed to demonstrate the potential use of WT1 to establish quality of remission in acute leukemia patients for early identification of patients at high risk of relapse.
  • A prospective study based on a quantitative Real-Time PCR (TaqMan) assay in 562 peripheral blood samples collected from 82 acute leukemia patients at diagnosis and during follow-up was established.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gene Expression Regulation, Neoplastic. Genes, Wilms Tumor. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / therapy. WT1 Proteins / blood

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443273.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; 0 / WT1 Proteins
  •  go-up   go-down


33. Fujimoto TT, Kishimoto M, Ide K, Mizushima M, Mita M, Sezaki N, Kojima K, Shinagawa K, Niiya K, Tanimoto M, Fujimura K: Glanzmann thrombasthenia with acute myeloid leukemia successfully treated by bone marrow transplantation. Int J Hematol; 2005 Jan;81(1):77-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glanzmann thrombasthenia with acute myeloid leukemia successfully treated by bone marrow transplantation.
  • We report successful treatment by bone marrow transplantation (BMT) in an acute myeloid leukemia (AML) patient with Glanzmann thrombasthenia (GT).
  • [MeSH-major] Bone Marrow Transplantation. Leukemia, Myeloid / complications. Leukemia, Myeloid / therapy. Thrombasthenia / complications. Thrombasthenia / therapy
  • [MeSH-minor] Acute Disease. Humans. Male. Middle Aged


34. Stanciu-Herrera C, Morgan C, Herrera L: Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines. Leuk Res; 2008 Apr;32(4):625-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines.
  • The monoclonal antibodies (MAbs) HD37 and RFB4 bind to receptors on precursor B acute lymphoblastic leukemia (ALL) cells.
  • HD37 and not RFB4 increased the in vitro cytotoxicity of daunorubicin (DNR) and vincristine (VCR) in three Pre-B ALL cell lines.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2003 Jan;127(1):42-8 [12521365.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):380-9 [11888077.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2787-99 [12860957.001]
  • [Cites] Anticancer Drugs. 2003 Oct;14(9):669-82 [14551500.001]
  • [Cites] Cytometry B Clin Cytom. 2003 Nov;56(1):30-42 [14582135.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1274-81 [14977825.001]
  • [Cites] Exp Cell Res. 2004 Aug 15;298(2):560-73 [15265702.001]
  • [Cites] J Immunol. 1987 May 1;138(9):2793-9 [2437199.001]
  • [Cites] Leuk Res. 1988;12(2):135-41 [3282129.001]
  • [Cites] Blood. 1988 Jul;72(1):299-307 [3291983.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4906-12 [2667754.001]
  • [Cites] J Immunol. 1991 Dec 1;147(11):3663-71 [1719083.001]
  • [Cites] Crit Rev Oncol Hematol. 1991 Dec;11(4):267-97 [1777090.001]
  • [Cites] Blood. 1992 Nov 1;80(9):2315-20 [1384801.001]
  • [Cites] Blood. 1993 Nov 1;82(9):2624-33 [8219217.001]
  • [Cites] Blood. 1994 Mar 1;83(5):1329-36 [7509655.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4048-52 [7513431.001]
  • [Cites] Curr Opin Oncol. 1994 Jan;6(1):14-22 [8204688.001]
  • [Cites] J Immunol. 1995 Apr 1;154(7):3096-104 [7534787.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3457-65 [7780133.001]
  • [Cites] Leuk Lymphoma. 1995 Aug;18(5-6):385-97 [8528044.001]
  • [Cites] Curr Biol. 1997 Feb 1;7(2):133-43 [9016707.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7509-14 [9207122.001]
  • [Cites] Leuk Res. 1998 Jul;22(7):567-79 [9680106.001]
  • [Cites] J Immunol. 1998 Sep 15;161(6):3176-85 [9743386.001]
  • [Cites] Exp Hematol. 2005 Feb;33(2):199-211 [15676214.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):694-704 [15681517.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3676-85 [15738535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15178-83 [16217038.001]
  • [Cites] Leukemia. 2003 Feb;17(2):334-8 [12592332.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):3920-7 [10632321.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1302-13 [10778955.001]
  • [Cites] Immunity. 2000 Jul;13(1):47-57 [10933394.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):800-9 [11564066.001]
  • [Cites] J Biol Chem. 2001 Nov 23;276(47):44315-22 [11551923.001]
  • [CommentIn] Leuk Res. 2008 Jun;32(6):847-9 [18191203.001]
  • (PMID = 17706771.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA101897-04; United States / NCI NIH HHS / CA / K01 CA101897-04
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Antigens, CD19; 0 / Antineoplastic Agents, Phytogenic; 0 / Sialic Acid Binding Ig-like Lectin 2; 5J49Q6B70F / Vincristine; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ NIHMS42262; NLM/ PMC2276361
  •  go-up   go-down


35. Nasr R, de Thé H: Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting. Int J Hematol; 2010 Jun;91(5):742-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
  • Acute promyelocytic leukemia (APL) is characterized by a t(15;17) translocation that yields a PML/RARA fusion protein.
  • RA also triggers growth arrest and progressive clearance of leukemia initiating cells (LIC), both ex vivo and in vivo.
  • Suboptimal RA concentrations or expression of the PLZF/RARA variant allows complete RA-induced differentiation, but neither LIC clearance nor disease remission.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Granulocyte Precursor Cells / drug effects. Leukemia, Promyelocytic, Acute / drug therapy. Oncogene Proteins, Fusion / genetics. Oxides / therapeutic use. Tretinoin / therapeutic use
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Humans. Mice. Oncogenes / drug effects

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2006 Dec;91(12 Suppl):ECR58 [17194664.001]
  • [Cites] J Exp Med. 2004 Apr 19;199(8):1163-74 [15096541.001]
  • [Cites] N Engl J Med. 1993 Jul 15;329(3):177-89 [8515790.001]
  • [Cites] Trends Cell Biol. 2005 Sep;15(9):494-501 [16084092.001]
  • [Cites] Mol Cell. 2000 May;5(5):811-20 [10882117.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10 ):821-7 [16175176.001]
  • [Cites] Blood. 1995 Feb 15;85(4):1083-94 [7849296.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):131-4 [16227315.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8754-65 [16204045.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]
  • [Cites] EMBO J. 2009 Jan 7;28(1):34-47 [19078967.001]
  • [Cites] Cancer Cell. 2006 Feb;9(2):73-4 [16473273.001]
  • [Cites] Blood. 1995 May 15;85(10):2643-53 [7742522.001]
  • [Cites] Blood. 2009 Dec 24;114(27):5499-511 [19855079.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2505-15 [18299451.001]
  • [Cites] Oncogene. 2001 Oct 29;20(49):7257-65 [11704854.001]
  • [Cites] Nat Med. 2008 Dec;14(12):1333-42 [19029980.001]
  • [Cites] Cell. 1997 Jul 11;90(1):97-107 [9230306.001]
  • [Cites] J Exp Med. 2002 Nov 18;196(10):1373-80 [12438428.001]
  • [Cites] Cancer Cell. 2007 Jul;12 (1):23-35 [17613434.001]
  • [Cites] Blood. 1998 Oct 1 ;92 (7):2244-51 [9746761.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1014-22 [11807007.001]
  • [Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]
  • [Cites] Blood. 2001 Jan 1;97(1):264-9 [11133770.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10173-8 [10954752.001]
  • [Cites] EMBO J. 1993 Mar;12(3):1161-7 [8384553.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):7-8 [19111876.001]
  • [Cites] Cancer Cell. 2007 Jul;12 (1):36-51 [17613435.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16608-13 [16275922.001]
  • [Cites] Nature. 2008 Jun 19;453(7198):1072-8 [18469801.001]
  • [Cites] Nat Cell Biol. 2008 May;10 (5):538-46 [18408734.001]
  • [Cites] J Exp Med. 2001 Jun 18;193(12 ):1361-71 [11413191.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Dec;8(12 ):1006-16 [17928811.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1043-52 [10190895.001]
  • [Cites] N Engl J Med. 2009 Feb 26;360(9):928-30 [19246367.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]
  • [Cites] Biochim Biophys Acta. 1997 Dec 9;1333(3):M53-61 [9426202.001]
  • [Cites] Blood. 2001 Jan 1;97(1):73-80 [11133744.001]
  • [Cites] Oncogene. 1996 Jun 6;12 (11):2451-9 [8649787.001]
  • [Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]
  • [Cites] Blood. 2006 May 1;107(9):3469-73 [16373661.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):811-4 [9486654.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):143-53 [15710327.001]
  • [Cites] Blood. 1999 May 15;93(10 ):3167-215 [10233871.001]
  • [Cites] Genes Dev. 2009 May 15;23 (10 ):1195-206 [19451220.001]
  • [Cites] Cancer Cell. 2007 Jun;11(6):513-25 [17560333.001]
  • [Cites] Nat Genet. 1998 Feb;18(2):126-35 [9462740.001]
  • [Cites] Leukemia. 1998 Nov;12(11):1829-33 [9823961.001]
  • [Cites] EMBO J. 1994 Mar 1;13(5):1073-83 [8131741.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14807-12 [10611294.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3445-58 [12032781.001]
  • [Cites] Clin Cancer Res. 2009 Oct 15;15(20):6321-6 [19808868.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9548-53 [16769902.001]
  • [Cites] Nat Cell Biol. 2008 May;10 (5):547-55 [18408733.001]
  • [Cites] Cell. 1994 Jan 28;76(2):333-43 [8293467.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1462-71 [19322209.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3978-83 [9108090.001]
  • [Cites] Leuk Lymphoma. 2006 Jun;47(6):1062-8 [16840198.001]
  • [Cites] Blood. 2009 Dec 24;114(27):5415-25 [19797526.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7 [19225113.001]
  • [Cites] Oncogene. 2001 Oct 29;20(49):7140-5 [11704842.001]
  • [Cites] Haematologica. 2007 Mar;92(3):323-31 [17339181.001]
  • [Cites] Blood. 1999 Jul 15;94(2):793-802 [10397747.001]
  • [Cites] Mol Cell. 2000 May;5(5):821-30 [10882118.001]
  • [Cites] Cancer Cell. 2010 Feb 17;17(2):173-85 [20159609.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):124-33 [9450572.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):815-8 [9486655.001]
  • (PMID = 20455087.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


36. Kim D, Kwok B, Steinberg A: Simultaneous acute myeloid leukemia and multiple myeloma successfully treated with allogeneic stem cell transplantation. South Med J; 2010 Dec;103(12):1246-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous acute myeloid leukemia and multiple myeloma successfully treated with allogeneic stem cell transplantation.
  • We present a case of concurrent diagnosis of acute myeloid leukemia (AML) with multiple myeloma with complex karyotype, which was successfully treated with allogeneic stem cell transplantation.
  • Bone marrow biopsy confirmed the simultaneous diagnosis of myeloma and AML.
  • He underwent an allogeneic stem cell transplant from his human lymphocyte antigen (HLA)-matched sibling, and is now disease-free approximately one year since the transplant.
  • He has mild graft-versus-host disease (GVHD).
  • To our knowledge, this is the first case of a patient with simultaneous AML and multiple myeloma who has undergone successful treatment with allogeneic stem cell transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / complications. Multiple Myeloma / complications. Neoplasms, Multiple Primary / therapy


37. Jeha S, Kantarjian H: Clofarabine for the treatment of acute lymphoblastic leukemia. Expert Rev Anticancer Ther; 2007 Feb;7(2):113-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clofarabine for the treatment of acute lymphoblastic leukemia.
  • A marked improvement in the outcome of patients with acute lymphoblastic leukemia has been achieved with chemotherapeutic agents developed between the 1950s and 1970s.
  • As the limits of optimizing the use of old drugs are reached, most adults with acute lymphoblastic leukemia still succumb to their disease and leukemia remains the leading cause of nonaccidental death in children.
  • Clofarabine, a next-generation deoxyadenosine analog, has demonstrated significant activity in children and adults with refractory lymphoid and myeloid leukemia in early clinical trials and was granted approval for use in children with acute lymphoblastic leukemia in second or higher relapse.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17288522.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  • [Number-of-references] 36
  •  go-up   go-down


38. Visser OJ, Perk LR, Zijlstra JM, van Dongen GA, Huijgens PC, van de Loosdrecht AA: Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease. BioDrugs; 2006;20(4):201-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease.
  • Recently, RIT has been introduced targeting the CD20 surface antigen, which is expressed on nearly all B-cell non-Hodgkin lymphomas (NHL).
  • In general, there is no organ-specific non-hematologic toxicity when a standard dose of RIT is used.
  • Treatment-related myelodysplastic syndromes and acute myeloid leukemia after RIT are being investigated but long-term data are needed for final evaluation.
  • RIT is feasible in heavily pretreated patients and does not compromise future treatments in the event of progressive disease.
  • Randomized phase III studies are in progress to evaluate the timing of RIT in the overall management of indolent NHLInvestigations of new emerging therapeutic strategies for patients with indolent NHL are underway, with research into the feasibility of RIT as first-line therapy and in advanced disease, RIT dose escalation and combined modality approaches with autologous stem cell transplantation.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy / methods
  • [MeSH-minor] Disease Progression. Feasibility Studies. Humans. Models, Biological. Recurrence. Treatment Outcome


39. Nodomi S, Kato I, Daifu T, Saida S, Morishima T, Matsubara H, Umeda K, Watanabe K, Maruya E, Saji H, Nakahata T, Adachi S: [Early relapse of hemophagocytic syndrome after reduced-intensity cord blood transplantation for relapsed acute lymphoblastic leukemia]. Rinsho Ketsueki; 2010 Mar;51(3):201-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early relapse of hemophagocytic syndrome after reduced-intensity cord blood transplantation for relapsed acute lymphoblastic leukemia].
  • We report a 4-year-old girl who presented with acute onset of hemophagocytic syndrome (HPS) after induction therapy and HPS relapsed immediately after reduced-intensity cord blood transplantation (RI-CBT) for relapse of acute lymphoblastic leukemia.
  • Prednisolone and cyclosporine were administered for prophylaxis against graft-versus-host disease.
  • [MeSH-major] Fetal Blood / transplantation. Lymphohistiocytosis, Hemophagocytic / etiology. Lymphohistiocytosis, Hemophagocytic / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Female. Graft vs Host Disease / prevention & control. Humans. Recurrence. Remission Induction. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379115.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


40. Cimino G, Cenfra N, Elia L, Sica S, Luppi M, Meloni G, Vignetti M, Paoloni F, Foà R, Mandelli F: The therapeutic response and clinical outcome of adults with ALL1(MLL)/AF4 fusion positive acute lymphoblastic leukemia according to the GIMEMA experience. Haematologica; 2010 May;95(5):837-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The therapeutic response and clinical outcome of adults with ALL1(MLL)/AF4 fusion positive acute lymphoblastic leukemia according to the GIMEMA experience.
  • The clinical outcome of 21 adults with ALL1(MLL)/AF4 positive acute lymphoblastic leukemia enrolled in the GIMEMA LAL 2000 trial and of 25 patients entered into the previous 0496 study is reported.
  • At 36 months, overall and disease free survivals were 32.9%, 31.8%, 28% and 27.3%, in LAL 2000 and 0496 trials, respectively.
  • Thus, ALL1(MLL)/AF4 abnormality characterized a subset of patients with adverse prognosis in which the overall strategy adopted in the LAL 2000 study, rather than transplants per se, failed to improve the patient clinical outcome.
  • [MeSH-major] Biomarkers, Tumor / genetics. DNA-Binding Proteins / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Nuclear Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cohort Studies. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Histone-Lysine N-Methyltransferase. Humans. Male. Middle Aged. Oncogene Proteins, Fusion. Remission Induction. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Blood. 2005 May 1;105(9):3434-41 [15650057.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2014-20 [12791662.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10735-9 [1720549.001]
  • [Cites] Cell. 1992 Nov 13;71(4):691-700 [1423624.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Leukemia. 2006 Dec;20(12):2155-61 [17039234.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1408-13 [17062730.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Cell. 1992 Nov 13;71(4):701-8 [1423625.001]
  • [Cites] Nat Genet. 1992 Oct;2(2):113-8 [1303259.001]
  • [Cites] Blood. 1993 Jul 15;82(2):544-6 [8329709.001]
  • [Cites] Blood. 1993 Nov 15;82(10):2943-7 [8219184.001]
  • [Cites] N Engl J Med. 1994 Feb 3;330(5):328-36 [8277954.001]
  • [Cites] Baillieres Clin Haematol. 1994 Jun;7(2):235-62 [7803900.001]
  • [Cites] Leukemia. 1995 Mar;9(3):391-5 [7885037.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1898-909 [9731046.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):417-20 [12124171.001]
  • (PMID = 20107154.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 150826-18-9 / AFF1 protein, human; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Other-IDs] NLM/ PMC2864392
  •  go-up   go-down


41. Glasow A, Prodromou N, Xu K, von Lindern M, Zelent A: Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways. Blood; 2005 Jan 1;105(1):341-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways.
  • Use of all-trans-retinoic acid (ATRA) in combinatorial differentiation therapy of acute promyelocytic leukemia (APL) results in exceptional cure rates.
  • However, potent cell differentiation effects of ATRA are so far largely restricted to this disease and long-term survival rates in non-APL acute myelogeneous leukemia (AML) remain unacceptably poor, requiring development of novel therapeutic strategies.
  • We demonstrate here that myelomonocytic growth factors (granulocyte colony-stimulating factor [G-CSF] and/or granulocyte macrophage colony-stimulating factor [GM-CSF]) potentiate differentiation effects of ATRA in different AML cell lines and primary cells from patients with myeloid leukemia.
  • Specific inhibitors of mitogen mitogen-activated protein kinase (MAPK) (MEK)-1/-2 or p38 extracellular signal-related kinase (ERK) kinase diminish the ATRA as well as ATRA and G/GM-CSF-induced activation of the RARalpha proteins and decreased the differentiation-induced decline in cell numbers.
  • Our data demonstrate that acting, at least in part, via the MAP kinase pathways, myelomonocytic growth factors enhance ATRA-dependent activation of the RARalpha isoforms and maturation of myeloid leukemia cells.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / pharmacology. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Leukemia, Myeloid / metabolism. Leukemia, Myeloid / pathology. MAP Kinase Signaling System / drug effects. Receptors, Retinoic Acid / metabolism. Tretinoin / pharmacology
  • [MeSH-minor] Animals. Cell Differentiation / drug effects. Cell Division / drug effects. Humans. Mice. Protein Isoforms / genetics. Protein Isoforms / metabolism. Response Elements / genetics. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15339853.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5688UTC01R / Tretinoin; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


42. Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, Stirewalt DL, Heerema NA, Raimondi SC, Hirsch B, Franklin JL, Lange B, Meshinchi S: Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood; 2010 Aug 05;116(5):702-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
  • Recent studies of WT1 mutations in acute myeloid leukemia (AML) mostly report an association with unfavorable clinical outcome.
  • However, FLT3/ITD was present in 36% of the WT1(mut) cohort; WT1(mut) patients without FLT3/ITD had similar OS (56% vs 56%, respectively; P = .8) and EFS (35% and 44%, respectively; P = .34) to patients who were wild type for both mutations.
  • [MeSH-major] Genes, Wilms Tumor. Leukemia, Myeloid / genetics. Mutation
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Cohort Studies. DNA Mutational Analysis. DNA, Neoplasm / genetics. Exons / genetics. Female. Humans. Infant. Infant, Newborn. Kaplan-Meier Estimate. Karyotyping. Male. Prevalence. Prognosis. Proportional Hazards Models. Retrospective Studies. Tandem Repeat Sequences / genetics. Treatment Outcome. Young Adult. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Jan 1;97(1):89-94 [11133746.001]
  • [Cites] Leukemia. 2007 May;21(5):868-76 [17361230.001]
  • [Cites] Br J Haematol. 2004 Jun;125(5):590-600 [15147374.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4140-6 [15483024.001]
  • [Cites] Leukemia. 1992 May;6(5):405-9 [1317488.001]
  • [Cites] Hum Mol Genet. 1994 Sep;3(9):1633-7 [7833922.001]
  • [Cites] Hum Mol Genet. 1995 Mar;4(3):351-8 [7795587.001]
  • [Cites] Biochemistry. 1996 Sep 17;35(37):12070-6 [8810912.001]
  • [Cites] Hum Mutat. 1997;9(3):209-25 [9090524.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9152-4 [16230371.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3654-61 [16912228.001]
  • [Cites] Curr Opin Hematol. 2007 Mar;14(2):106-14 [17255787.001]
  • [Cites] Leukemia. 2007 Mar;21(3):550-1; author reply 552 [17205055.001]
  • [Cites] Blood. 2007 Aug 1;110(3):979-85 [17440048.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1044-53 [18000167.001]
  • [Cites] Leukemia. 2008 May;22(5):915-31 [18288131.001]
  • [Cites] Semin Oncol. 2008 Aug;35(4):346-55 [18692685.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5429-35 [18591546.001]
  • [Cites] Blood. 2009 May 7;113(19):4505-11 [19221039.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5951-60 [19171881.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6558-66 [19304957.001]
  • [Cites] Cancer. 2009 Aug 15;115(16):3719-27 [19536888.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1472-9 [19322206.001]
  • [Cites] Pediatr Blood Cancer. 2009 Dec;53(6):1136-9 [19618455.001]
  • [Cites] Blood. 2010 Mar 25;115(12):2372-9 [20056794.001]
  • [Cites] Gene. 2001 Aug 8;273(2):141-61 [11595161.001]
  • (PMID = 20413658.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00002798/ NCT00070174
  • [Grant] United States / NCI NIH HHS / CA / R01 CA114563; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / R21CA10262-01; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC2918327
  •  go-up   go-down


43. Fujisawa S, Tanioka F, Matsuoka T, Ozawa T, Naito K, Kobayashi M: CD7/CD19 double-positive T-cell acute lymphoblastic leukemia. Int J Hematol; 2006 May;83(4):324-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD7/CD19 double-positive T-cell acute lymphoblastic leukemia.
  • We report a rare case of T-cell acute lymphoblastic leukemia (T-ALL) with an aberrant phenotype.
  • Neither T-cell receptor gamma nor immunoglobulin heavy chain rearrangement was detected in the neck LN.
  • The patient is now under maintenance therapy in the first CR without hematopoietic cell transplantation.
  • [MeSH-major] Antigens, CD19. Antigens, CD7. Head and Neck Neoplasms / drug therapy. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Pleural Effusion, Malignant / drug therapy
  • [MeSH-minor] Disease-Free Survival. Humans. Male. Middle Aged. Radiography. Remission Induction


44. Galbizo E, Williams LA: Chronic graft-versus-host disease. Oncol Nurs Forum; 2006 Sep;33(5):881-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic graft-versus-host disease.
  • [MeSH-major] Graft vs Host Disease / drug therapy. Graft vs Host Disease / pathology. Immunosuppressive Agents / therapeutic use
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Chronic Disease. Disease Progression. Humans. Leukemia, Myeloid, Acute / therapy. Male. Middle Aged. Prognosis. Risk Factors. Stem Cell Transplantation. Tacrolimus / therapeutic use

  • Genetic Alliance. consumer health - Chronic Graft versus Host Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16986223.001).
  • [ISSN] 1538-0688
  • [Journal-full-title] Oncology nursing forum
  • [ISO-abbreviation] Oncol Nurs Forum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Immunosuppressive Agents; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


45. Jaff N, Chelghoum Y, Elhamri M, Tigaud I, Michallet M, Thomas X: Trisomy 8 as sole anomaly or with other clonal aberrations in acute myeloid leukemia: impact on clinical presentation and outcome. Leuk Res; 2007 Jan;31(1):67-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trisomy 8 as sole anomaly or with other clonal aberrations in acute myeloid leukemia: impact on clinical presentation and outcome.
  • One hundred and fifty-four acute myeloid leukemia patients with trisomy 8 were studied for their clinical and biological characteristics, and treatment outcome.
  • Median disease-free survival (DFS) and overall survival (OS) were 7.8 and 8.3 months, respectively.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 8. Leukemia, Myeloid / genetics. Leukemia, Myeloid, Acute / genetics. Trisomy / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16814381.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


46. Berköz M, Yalin S: Association of CYP2B6 G15631T polymorphism with acute leukemia susceptibility. Leuk Res; 2009 Jul;33(7):919-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of CYP2B6 G15631T polymorphism with acute leukemia susceptibility.
  • In this study, we aimed to determine whether any association exists between genetic polymorphism in CYP2B6G15631T and individual susceptibility to acute leukemia.
  • Our study group consisted of 80 acute leukemia patients and 100 unrelated healthy volunteers as a control group.
  • 44 of the acute leukemia patients were diagnosed with acute lymphoblastic leukemia (ALL) and 36 patients with acute myeloid leukemia (AML).
  • The frequencies of GG genotype (wild type) were 40.9%, 50% and 67% in ALL, AML and control groups, respectively.
  • The TT genotype (homozygous variant) was not observed in either control or leukemia cases.
  • Logistic regression analyses showed a significant correlation between the CYP2B6 G15631T polymorphism (GT) and acute leukemia patients (OR=2.481, 95% CI=1.353-4.551, p=0.003).
  • Our findings indicate that GT genotype may be an important genetic determinant for acute leukemias.
  • According to our knowledge, this is the first report of an association between acute leukemia cases and the CYP2B6 G15631T polymorphism.
  • [MeSH-major] Aryl Hydrocarbon Hydroxylases / genetics. Leukemia, Myeloid, Acute / genetics. Oxidoreductases, N-Demethylating / genetics. Polymorphism, Genetic / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Child. Child, Preschool. Cytochrome P-450 CYP2B6. DNA, Neoplasm / genetics. Disease Susceptibility. Genotype. Humans. Middle Aged. Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144407.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP2B6 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP2B6; EC 1.5.- / Oxidoreductases, N-Demethylating
  •  go-up   go-down


47. Li L, Xiao ZJ: [Research update on pharmacogenomics in acute leukemia - review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun;16(3):704-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Research update on pharmacogenomics in acute leukemia - review].
  • Pharmacogenomics, a new subject aiming to elucidate genetic basis for inter individual differences in response on a drug and to predict the safety and efficacy of drugs by the genetic information, which guides to clinical individual therapy, breaks a new way to apply drugs rationally to acute leukemia.
  • This article reviewed the enzymes related to metabolism, transport and acting point of the drugs used in the treatment of acute leukemia and discussed the influence of their coding gene's polymorphism on drug adverse effects and disease prognosis.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18549659.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Number-of-references] 44
  •  go-up   go-down


48. Ozdogu H, Boga C, Yilmaz Z, Sahin FI, Bal N: Long-term colchicine therapy in a patient with Behçet's disease and acute promyelocytic leukemia. Rheumatol Int; 2007 Jun;27(8):763-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term colchicine therapy in a patient with Behçet's disease and acute promyelocytic leukemia.
  • Behçet's disease causes a continuous T-lymphocytic mediated inflammatory reaction in the small arterioles, which results in gradual destruction of any human organ or system.
  • The benefit of treatment with colchicine in patients with Behçet's disease has been reported in literature.
  • Acute leukemia has seldom been associated with Behçet's disease, although acute promyelocytic leukemia is a particular subtype of leukemia that is often characterized by special cytogenetic abnormalities.
  • We report a male patient with acute promyelocytic leukemia and Behçet's disease who had received long-term treatment with colchicine.
  • To our knowledge, this is the first report of the concomitant occurrence of acute promyelocytic leukemia and Behçet's disease, which suggests that long-term colchicine therapy has a role in the pathogenesis of acute promyelocytic leukemia.
  • At the time of this writing, his disease is in clinical remission.
  • [MeSH-major] Behcet Syndrome / drug therapy. Colchicine / adverse effects. Gout Suppressants / adverse effects. Leukemia, Promyelocytic, Acute / complications

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • Hazardous Substances Data Bank. COLCHICINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 1992 Sep;16(9):929-35 [1405722.001]
  • [Cites] Ann Med Interne (Paris). 1992;143(7):479-80 [1300872.001]
  • [Cites] Clin Exp Rheumatol. 1984 Apr-Jun;2(2):173-5 [6532622.001]
  • [Cites] Blood. 1994 Jan 1;83(1):10-25 [8274729.001]
  • [Cites] Curr Opin Pharmacol. 2004 Apr;4(2):183-8 [15063364.001]
  • [Cites] Mutat Res. 2001 Aug 22;495(1-2):51-9 [11448642.001]
  • [Cites] Ann Dermatol Venereol. 2002 Dec;129(12):1365-9 [12536172.001]
  • [Cites] South Med J. 2003 Mar;96(3):323-4 [12659376.001]
  • [Cites] J Exp Med. 1989 Jul 1;170(1):15-26 [2664067.001]
  • [Cites] Br J Dermatol. 1997 Aug;137(2):317-8 [9292097.001]
  • [Cites] Mutat Res. 2001 Jun 27;493(1-2):101-14 [11516720.001]
  • [Cites] Am J Physiol. 1991 Oct;261(4 Pt 1):L315-21 [1928366.001]
  • (PMID = 17177066.001).
  • [ISSN] 0172-8172
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Gout Suppressants; SML2Y3J35T / Colchicine
  •  go-up   go-down


49. Turriziani M, Caporaso P, Bonmassar L, Buccisano F, Amadori S, Venditti A, Cantonetti M, D'Atri S, Bonmassar E: O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro. Pharmacol Res; 2006 Apr;53(4):317-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro.
  • Previous studies performed by our group and a more recent clinical investigation reported by Karen Seiter, pointed out that triazene compounds could play an important role in the treatment of refractory acute leukaemia.
  • Leukaemia blasts, especially of lymphoblastic leukaemia, show frequently high levels of MGMT activity.
  • Therefore, it reasonable to hypothesize that combined treatment of leukaemia patients with triazene compounds along with MGMT inhibitors could lead to a better control of the disease.
  • The present report describes, for the first time, pre-clinical in vitro studies on the cytotoxic activity of combined treatment with PAT+TMZ against long-term cultured leukaemia cells and primary leukaemia blasts obtained from patients with acute lymphoblastic leukaemia or acute myeloblastic leukaemia.
  • The results point out that, both in long-term cultured leukaemia cell lines and in primary blast samples, PAT could improve dramatically the sensitivity of malignant cells to the cytotoxic effects of TMZ.
  • This sensitizing effect is detectable when leukaemia cells show resistance mechanisms based on a MGMT-proficient phenotype.
  • In conclusion, these results appear to provide disease-oriented rational basis to design novel clinical protocols for the treatment of acute leukaemia with combined administration of PAT and triazene compounds.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Dacarbazine / analogs & derivatives. Guanine / analogs & derivatives. Leukemia, Myeloid / drug therapy. O(6)-Methylguanine-DNA Methyltransferase / antagonists & inhibitors
  • [MeSH-minor] Acute Disease. Drug Synergism. HL-60 Cells. Humans. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / pathology. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. GUANINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16412662.001).
  • [ISSN] 1043-6618
  • [Journal-full-title] Pharmacological research
  • [ISO-abbreviation] Pharmacol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / O(6)-(4-bromothenyl)guanine; 5Z93L87A1R / Guanine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


50. Galbraith D, Gross SA, Paustenbach D: Benzene and human health: A historical review and appraisal of associations with various diseases. Crit Rev Toxicol; 2010 Nov;40 Suppl 2:1-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over the last century, benzene has been a well-studied chemical, with some acute and chronic exposures being directly associated with observed hematologic effects in humans and animals.
  • Chronic heavy exposures to benzene have also been associated with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) in humans.
  • Other disease processes have also been studied, but have generally not been supported by epidemiologic studies of workers using benzene in the workplace.
  • Within occupational cohorts with large populations and very low airborne benzene exposures (less than 0.1–1.0 ppm), it can be difficult to separate background disease incidence from those occurring due to occupational exposures.
  • In the last few decades, some scientists and physicians have suggested that chronic exposures to various airborne concentrations of benzene may increase the risk of developing non-Hodgkin's lymphoma (NHL) (Savitz and Andrews, 1997, Am J Ind Med 31:287–295; Smith et al., 2007, Cancer Epidemiol Biomarkers Prev 16:385–391), multiple myeloma (MM) (Goldstein, 1990, Ann NY Acad Sci 609:225–230; Infante, 2006, Ann NY Acad Sci 1076:90–109), and various other hematopoietic disorders.
  • Our evaluation indicates that the only malignant hematopoietic disease that has been clearly linked to benzene exposure is AML.
  • [MeSH-minor] Female. History, 20th Century. History, 21st Century. Humans. Leukemia, Myeloid, Acute / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Male. Multiple Myeloma / epidemiology. Myelodysplastic Syndromes / epidemiology. Workplace

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. BENZENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20939751.001).
  • [ISSN] 1547-6898
  • [Journal-full-title] Critical reviews in toxicology
  • [ISO-abbreviation] Crit. Rev. Toxicol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] J64922108F / Benzene
  •  go-up   go-down


51. Gerritsen A, Lam K, Marion Schneider E, van den Heuvel-Eibrink MM: An exclusive case of juvenile myelomonocytic leukemia in association with Kikuchi's disease and hemophagocytic lymphohistiocytosis and a review of the literature. Leuk Res; 2006 Oct;30(10):1299-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An exclusive case of juvenile myelomonocytic leukemia in association with Kikuchi's disease and hemophagocytic lymphohistiocytosis and a review of the literature.
  • We present a case of juvenile myelomonocytic leukemia (JMML) accompanied by immune-mediated hemophagocytic lymphohistiocytosis (HLH) and Kikuchi's disease, both as a paraneoplastic phenomenon.
  • Our patient was treated with prednisolone according to the few described cases of HLH and Kikuchi's disease in non-JMML patients, resulting in disappearance of the clinical symptoms.
  • [MeSH-major] Histiocytic Necrotizing Lymphadenitis / complications. Leukemia, Myelomonocytic, Acute / complications. Lymphohistiocytosis, Hemophagocytic / complications. Lymphohistiocytosis, Hemophagocytic / drug therapy. Prednisolone / therapeutic use


52. Ishikawa N, Tajima G, Yofune N, Nishimura S, Kobayashi M: Moyamoya syndrome after cranial irradiation for bone marrow transplantation in a patient with acute leukemia. Neuropediatrics; 2006 Dec;37(6):364-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Moyamoya syndrome after cranial irradiation for bone marrow transplantation in a patient with acute leukemia.
  • However, we could find only three cases of prophylactic cranial irradiation for hematological disorders and no case of cranial irradiation before bone marrow transplantation in patients with acute leukemia.
  • We recently treated a boy who developed moyamoya vessels 1.5 years after cranial irradiation for bone marrow transplantation for acute leukemia.
  • [MeSH-major] Bone Marrow Transplantation. Cerebral Arteries / radiation effects. Cranial Irradiation / adverse effects. Leukemia / radiotherapy. Moyamoya Disease / diagnosis. Radiation Injuries / diagnosis
  • [MeSH-minor] Acute Disease. Angiography, Digital Subtraction. Carotid Artery, Internal / radiation effects. Carotid Artery, Internal / surgery. Carotid Stenosis / diagnosis. Carotid Stenosis / surgery. Cerebral Angiography. Cerebral Infarction / diagnosis. Cerebral Infarction / surgery. Cerebral Revascularization. Child. Follow-Up Studies. Humans. Ischemic Attack, Transient / diagnosis. Ischemic Attack, Transient / surgery. Magnetic Resonance Imaging. Male


53. de Greef GE, van Putten WL, Boogaerts M, Huijgens PC, Verdonck LF, Vellenga E, Theobald M, Jacky E, Löwenberg B, Dutch-Belgian Hemato-Oncology Co-operative Group HOVON, Swiss Group for Clinical Cancer Research SAKK: Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. Br J Haematol; 2005 Jan;128(2):184-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies.
  • Complete remission (CR) in patients with acute myeloid leukaemia (AML) is the primary endpoint for the evaluation of induction treatment and treatment strategies.
  • This study examined the individual parameters for CR in 1250 adult patients with de novo AML treated according to three successive study protocols.
  • This was independent of blast cells present in the peripheral blood or bone marrow (BM) cellularity.
  • In the same patient group, the presence of extramedullary leukaemia, incomplete platelet (<100 x 10(9)/l) or neutrophil (<1.0 x 10(9)/l) recovery caused a reduced OS and increased RR.
  • In conclusion, < or =5% blasts in the BM, recovery of neutrophils and platelets, and the absence of extramedullary disease constitute the cornerstones for the definition of a haematological CR in patients with AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Disease-Free Survival. Female. Humans. Lymphocyte Count. Male. Middle Aged. Proportional Hazards Models. Recurrence. Remission Induction. Risk

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2005 Apr;129(1):157-8; author reply 158 [15801968.001]
  • (PMID = 15638852.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


54. Brisco MJ, Latham S, Sutton R, Hughes E, Wilczek V, van Zanten K, Budgen B, Bahar AY, Malec M, Sykes PJ, Kuss BJ, Waters K, Venn NC, Giles JE, Haber M, Norris MD, Marshall GM, Morley AA: Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia. J Mol Diagn; 2009 May;11(3):194-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.
  • Molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia were identified by determining, at the time of diagnosis, the repertoire of rearrangements of the immunoglobulin heavy chain (IGH) gene using segment-specific variable (V), diversity (D), and junctional (J) primers in two different studies that involved a total study population of 75 children and 18 adults.
  • Some minor clones were quite large and a proportion of them would not be able to be detected by a minimal residual disease test directed to the marker for the major clone.
  • IGH repertoire analysis at diagnosis has potential advantages for the identification of molecular markers for the quantification of minimal residual disease in acute lymphoblastic leukemia cases.
  • [MeSH-major] Cell Lineage. Gene Rearrangement, B-Lymphocyte. Immunoglobulin Heavy Chains / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Aug;14(8):1426-35 [10942239.001]
  • [Cites] J Mol Diagn. 2009 May;11(3):201-10 [19324989.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2315-23 [11895762.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Mar;15(1):71-90 [11987917.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4520-6 [12946997.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Leukemia. 2004 May;18(5):934-8 [15029212.001]
  • [Cites] Blood. 2004 May 15;103(10):3798-804 [14656882.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W435-40 [15215425.001]
  • [Cites] Blood. 1987 Oct;70(4):1079-83 [3477297.001]
  • [Cites] Leukemia. 1990 Nov;4(11):727-31 [2172664.001]
  • [Cites] Blood. 1993 Jul 15;82(2):581-9 [8329713.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):196-200 [7904666.001]
  • [Cites] Leukemia. 1995 Nov;9(11):1847-50 [7475273.001]
  • [Cites] Leukemia. 1997 Dec;11(12):2192-9 [9447840.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):591-8 [9718378.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] Leukemia. 1999 Jan;13(1):110-8 [10049045.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D593-7 [15608269.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Leukemia. 2007 Apr;21(4):706-13 [17287857.001]
  • [Cites] Blood. 2007 Jul 15;110(2):632-9 [17371950.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1607-11 [17485550.001]
  • [Cites] Leukemia. 2008 Apr;22(4):771-82 [18239620.001]
  • [Cites] Leukemia. 2001 Jan;15(1):134-40 [11243381.001]
  • (PMID = 19324994.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers; 0 / Immunoglobulin Heavy Chains
  • [Other-IDs] NLM/ PMC2671336
  •  go-up   go-down


55. Foster N, Paulsson K, Sales M, Cunningham J, Groves M, O'Connor N, Begum S, Stubbs T, McMullan DJ, Griffiths M, Pratt N, Tauro S: Molecular characterisation of a recurrent, semi-cryptic RUNX1 translocation t(7;21) in myelodysplastic syndrome and acute myeloid leukaemia. Br J Haematol; 2010 Mar;148(6):938-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterisation of a recurrent, semi-cryptic RUNX1 translocation t(7;21) in myelodysplastic syndrome and acute myeloid leukaemia.
  • A proportion of cytogenetic abnormalities in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) may escape detection by high-resolution genomic technologies, but can be identified by conventional cytogenetic and molecular analysis.
  • Here, we report the detection of a reciprocal translocation t(7;21)(p22;q22) in the marrow of two adults with MDS and AML, using conventional cytogenetic analysis and fluorescence-in situ-hybridization (FISH).
  • Thus, our studies have identified t(7;21)(p22;q22) as a rare but recurrent abnormality in MDS/AML, with the existence of alternative spliced forms of the RUNX1-USP42 transcript in different patients.
  • Further studies are required to identify the potential contribution of these splice-variants to disease heterogeneity.
  • [MeSH-major] Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 7 / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Leukemia, Myeloid, Acute / genetics. Myelodysplastic Syndromes / genetics. Translocation, Genetic


56. Fender AB, Gust A, Wang N, Scott GA, Mercurio MG: Congenital leukemia cutis. Pediatr Dermatol; 2008 Jan-Feb;25(1):34-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital leukemia cutis.
  • Immunohistochemical stains and bone marrow examination confirmed a diagnosis of acute myelogenous leukemia.
  • A split in the mixed lineage leukemia gene was identified by fluorescence in situ hybridization.
  • As leukemia cutis more typically presents as multiple infiltrative papules, nodules, or plaques, we stress the importance of including leukemia in the differential diagnosis of a solitary nodule in a neonate.
  • [MeSH-major] Infant, Premature. Leukemia, Myeloid, Acute / congenital. Leukemia, Myeloid, Acute / pathology. Neoplasm Invasiveness / pathology. Skin Neoplasms / congenital. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Bone Marrow / pathology. Chromosome Aberrations. Chromosomes, Human, X. Cytogenetics / methods. Disease Progression. Fatal Outcome. Female. Humans. Immunohistochemistry. Infant, Newborn. Karyotyping. Risk Assessment

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Premature Babies.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18304150.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Cantor AB: GATA transcription factors in hematologic disease. Int J Hematol; 2005 Jun;81(5):378-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GATA transcription factors in hematologic disease.
  • Over the past few years, mutations in the gene encoding GATA-1 have been linked to several human hematologic disorders, including X-linked dyserythropoietic anemia and thrombocytopenia, X-linked thrombocytopenia and beta-thalassemia, and Down syndrome acute megakaryoblastic leukemia.
  • This review summarizes the role of GATA-1 during normal hematopoiesis and discusses how disease-associated mutations may affect its function.
  • [MeSH-minor] Anemia / genetics. Erythroid-Specific DNA-Binding Factors. GATA1 Transcription Factor. Hematopoiesis. Humans. Leukemia / genetics. Mutation

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Jun 1;101(11):4301-4 [12586620.001]
  • [Cites] Oncogene. 1989 Dec;4(12):1449-56 [2594367.001]
  • [Cites] Genes Dev. 1998 Apr 15;12(8):1176-88 [9553047.001]
  • [Cites] Lancet. 2003 May 10;361(9369):1617-20 [12747884.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):23491-8 [10438528.001]
  • [Cites] Nat Med. 2004 Mar;10(3):299-304 [14966519.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1398-411 [10364157.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12355-8 [8901585.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):166-75 [10508512.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3136-47 [15297311.001]
  • [Cites] Blood. 2003 Aug 1;102(3):981-6 [12649131.001]
  • [Cites] Mol Cell Biol. 2002 May;22(9):3121-8 [11940669.001]
  • [Cites] EMBO J. 2003 Dec 15;22(24):6516-25 [14657024.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1123-32 [12149188.001]
  • [Cites] EMBO J. 1999 May 17;18(10):2812-22 [10329627.001]
  • [Cites] Mol Cell Biol. 1996 May;16(5):2238-47 [8628290.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3965-73 [9233806.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11598-602 [8524811.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):502-13 [12094236.001]
  • [Cites] Cell. 1997 Jul 11;90(1):109-19 [9230307.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9623-7 [7568185.001]
  • [Cites] Blood. 2000 Apr 15;95(8):2543-51 [10753833.001]
  • [Cites] Methods. 2002 Jan;26(1):84-92 [12054907.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):476-81 [14695898.001]
  • [Cites] J Biol Chem. 2000 Jul 7;275(27):20762-9 [10801815.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):956-61 [9927675.001]
  • [Cites] Hum Genet. 2003 Jan;112(1):42-9 [12483298.001]
  • [Cites] Hum Mol Genet. 2002 Jan 15;11(2):147-52 [11809723.001]
  • [Cites] EMBO J. 2002 Oct 1;21(19):5225-34 [12356738.001]
  • [Cites] Blood. 1999 May 1;93(9):2867-75 [10216081.001]
  • [Cites] Blood. 1996 May 15;87(10):4025-39 [8639758.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4298-300 [12560215.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):980-5 [14715908.001]
  • [Cites] Genes Dev. 1997 Nov 15;11(22):3096-108 [9367990.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2641-8 [11023493.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9237-42 [12077323.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2040-5 [12200364.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3368-76 [12032775.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4333-41 [12576332.001]
  • [Cites] Blood. 1993 Nov 15;82(10):2998-3004 [8219191.001]
  • [Cites] Nature. 1989 Jun 8;339(6224):446-51 [2725678.001]
  • [Cites] J Biol Chem. 2000 Nov 3;275(44):34114-21 [10926935.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1573-7 [8079170.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3242-3 [15070711.001]
  • [Cites] Mol Cell Biol. 1999 Jun;19(6):4495-502 [10330188.001]
  • [Cites] Mol Cell. 1999 Feb;3(2):219-28 [10078204.001]
  • [Cites] Blood. 1993 Jun 15;81(12):3234-41 [8507862.001]
  • [Cites] Cell. 1989 Sep 8;58(5):877-85 [2776214.001]
  • [Cites] Blood. 2001 Jul 1;98(1):85-92 [11418466.001]
  • [Cites] J Exp Med. 2001 Nov 19;194(10):1461-71 [11714753.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2960-8 [12816863.001]
  • [Cites] EMBO J. 1996 Oct 15;15(20):5647-58 [8896458.001]
  • [Cites] Blood Cells Mol Dis. 2003 Nov-Dec;31(3):351-6 [14636651.001]
  • [Cites] Nature. 1993 Apr 1;362(6419):466-8 [8464479.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):148-52 [12172547.001]
  • [Cites] EMBO J. 2001 Sep 17;20(18):5250-60 [11566888.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):266-70 [10700180.001]
  • (PMID = 16158817.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL075705
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Erythroid-Specific DNA-Binding Factors; 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human; 0 / Transcription Factors
  • [Number-of-references] 59
  •  go-up   go-down


58. Loh AH, Chui CH: Port-A-Cath insertions in acute leukaemia and childhood malignancies. Asian J Surg; 2007 Jul;30(3):193-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Port-A-Cath insertions in acute leukaemia and childhood malignancies.
  • Incidence of catheter-related bloodstream infections (CRBSIs), other complications and CRBSI-related port removals were analysed for cases with acute leukaemia versus other malignancies.
  • While mean preoperative platelet count was 125.34 x 10(9)/L in children with acute leukaemia and 392.11 x 10(9)/L in those with other malignancies (p < 0.01), the incidence of all complications were similar between both subgroups.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638639.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


59. Xicoy B, Ribera JM, Oriol A, Sanz MA, Abella E, Tormo M, del Potro E, Bueno J, Grande C, Fernández-Calvo J, Orts M, Novo A, Rivas C, Hernández-Rivas JM, Feliu E, Ortega JJ: [Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients]. Med Clin (Barc); 2006 Jan 21;126(2):41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients].
  • [Transliterated title] Significado pronóstico de los subtipos inmunológicos de la leucemia aguda linfoblástica T del adulto. Estudio de 81 pacientes.
  • BACKGROUND AND OBJECTIVE: T-cell acute lymphoblastic leukemia (ALL) includes 4 immunological subtypes: pro-T, pre-T, thymic or cortical and mature.
  • The objective of this study was to describe the clinical characteristics, the result of treatment and the prognosis of the immunological subtypes of T-cell ALL in 81 adult patients included in 2 protocols of the Spanish PETHEMA group (ALL-96 and ALL-93).
  • The main clinical and biological parameters as well as the rate of response to treatment, the frequency of complete remission , disease free survival and overall survival were compared in each T-cell ALL subtype.
  • Patients with mature T-cell ALL had a slow rate of response to treatment in comparison with patients wit pre-T and mature T-cell ALL but this did not translate to significant differences in frequency of complete remission (77% vs 94%), disease free survival (42% vs 46%) and overall survival (29% vs 47%).
  • CONCLUSIONS: Although patients with mature T-cell ALL had a slow rate of response to treatment and their survival tended to be shorter, in the present study there were no statistically significant differences in the prognosis of the different subtypes of T-cell ALL.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426542.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


60. Kim ST, Jung CW, Lee J, Kwon JM, Oh SY, Park BB, Lee HR, Kim HJ, Kim K, Kim WS, Ahn JS, Kang WK, Park K: Postremission therapy for acute myeloid leukemia in the first remission. Leuk Lymphoma; 2007 May;48(5):937-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postremission therapy for acute myeloid leukemia in the first remission.
  • The medical records of 99 patients with acute myeloid leukemia (AML; except AML, M3) in the first remission from 1995 to 2004 were retrospectively reviewed.
  • When they achieved complete remission, at first complete remission (CR1), patients received allogeneic (n = 23), autologous hematopoietic stem cell transplantation (HSCT) (n = 35), or intensive chemotherapy (n = 41) according to prognostic factors and donor availability.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Hematopoietic Stem Cell Transplantation / methods. Humans. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Time Factors. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487738.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


61. Gong JY, Liu XP, Li CW, Zhao XC, Dai Y, Qin S, Xiao JG, Huang Q, Xu FY, Wang F, Cui W, Liu SH, Wang JX: [Clinical and laboratory study of a complex translocation t (6; 21; 8) (p22; q22; q22) in two patients with acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2006 May;27(5):314-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and laboratory study of a complex translocation t (6; 21; 8) (p22; q22; q22) in two patients with acute myeloid leukemia].
  • OBJECTIVE: To investigate the clinical and laboratory characteristics of a complex translocation t (6; 21;.
  • q22) in two patients with acute myeloid leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 6 / genetics. Chromosomes, Human, Pair 8 / genetics. Leukemia, Myeloid / genetics. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Adolescent. Chromosome Banding. Core Binding Factor Alpha 2 Subunit / genetics. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875580.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


62. Paralkar VR, Goradia A, Luger SM, Loren AW: Severe eosinophilia as a manifestation of acute graft-versus-host disease. Oncology; 2008;75(3-4):134-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe eosinophilia as a manifestation of acute graft-versus-host disease.
  • Significant peripheral eosinophilia in association with acute graft-versus-host disease (GVHD) is rare.
  • Here we report a case of eosinophilia in a 30-year-old woman with relapsed acute myelogenous leukemia after an allogeneic bone marrow transplant who was treated with donor lymphocyte infusion (DLI).
  • A diagnosis of acute GVHD was made and the patient was treated with corticosteroids with a resolution of all of the aforementioned findings.
  • [MeSH-major] Eosinophilia / diagnosis. Graft vs Host Disease / diagnosis. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adult. Bone Marrow Transplantation. Female. Glucocorticoids / therapeutic use. Graft vs Leukemia Effect. Humans. Lymphocyte Transfusion. Neoplasm Recurrence, Local / diagnosis. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18791329.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


63. Jiao B, Wu CF, Liang Y, Chen HM, Xiong SM, Chen B, Shi JY, Wang YY, Wang JH, Chen Y, Li JM, Gu LJ, Tang JY, Shen ZX, Gu BW, Zhao WL, Chen Z, Chen SJ: AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Leukemia; 2009 Sep;23(9):1598-604
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2.
  • AML1-ETO fusion gene is generated from chromosomal translocation t(8;21) mainly in acute myeloid leukemia M2 subtype (AML-M2).
  • Its spliced variant transcript, AML1-ETO9a, rapidly induces leukemia in murine model.
  • Taken together, these data suggest that AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) AML-M2.
  • [MeSH-major] Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Core Binding Factor Alpha 2 Subunit / genetics. Leukemia, Myeloid, Acute / genetics. Mutation. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Proteins c-kit / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19458628.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


64. Matloub Y, Lindemulder S, Gaynon PS, Sather H, La M, Broxson E, Yanofsky R, Hutchinson R, Heerema NA, Nachman J, Blake M, Wells LM, Sorrell AD, Masterson M, Kelleher JF, Stork LC, Children's Oncology Group: Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood; 2006 Aug 15;108(4):1165-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.
  • The Children's Cancer Group (CCG) 1952 clinical trial for children with standard-risk acute lymphoblastic leukemia (SR-ALL) compared intrathecal (IT) methotrexate (MTX) with IT triples (ITT) (MTX, cytarabine, and hydrocortisone sodium succinate [HSS]) as presymptomatic central nervous system (CNS) treatment.
  • Significantly more relapses occurred in bone marrow (BM) and testicles with ITT than IT MTX, particularly among patients with T-cell phenotype or day 14 BM aspirate containing 5% to 25% blasts.


65. Camera A, Rinaldi CR, Palmieri S, Cantore N, Mele G, Mettivier V, Miraglia E, Mastrullo L, Grimaldi F, Luciano L, Guerriero A, Rotoli B, Ferrara F: Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients. Ann Hematol; 2009 Feb;88(2):151-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
  • A large proportion of adult patients with acute myeloid leukemia (AML) relapse after treatment, and some of them are resistant to primary induction chemotherapy.
  • Sixty-one patients from seven hematological centers with poor-risk AML, primary refractory (n = 16), or relapsed (n = 45) were treated with a salvage regimen, including fludarabine (2 days) and cytarabine (3 days) in a sequential continuous infusion, associated with liposomal daunorubicin (3 days) (FLAD).
  • Nineteen patients in complete remission (CR) underwent a stem-cell transplant (SCT) procedure: five autologous, nine from a HL-A identical sibling, and five from HL-A matched unrelated donors.
  • Nine patients are alive and disease free; three of them were rescued after a further cytotoxic treatment.
  • A better response rate was obtained in the subgroup of relapsed patients, compared to patients treated for refractory disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / therapeutic use. Daunorubicin / administration & dosage. Daunorubicin / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Infusions, Intravenous. Liposomes. Male. Middle Aged. Recurrence. Salvage Therapy. Stem Cell Transplantation. Survival Rate. Time Factors


66. Schlenk RF, Fröhling S, Hartmann F, Fischer JT, Glasmacher A, Del Valle F, Götze K, Nerl C, Schoch R, Pralle H, Mergenthaler HG, Hensel M, Koller E, Kirchen H, Matzdorff A, Salwender H, Biedermann HG, Kremers S, Haase D, Benner A, Döhner K, Döhner H: Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial. Leukemia; 2006 Apr;20(4):748-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Administration, Oral. Aged. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Idarubicin / administration & dosage. Injections, Intravenous. Male. Middle Aged. Recurrence. Remission Induction. Survival Rate. Treatment Outcome. Tretinoin / administration & dosage

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437135.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Letter; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 5688UTC01R / Tretinoin; 6PLQ3CP4P3 / Etoposide; ZRP63D75JW / Idarubicin
  •  go-up   go-down


67. Bhojwani D, Moskowitz N, Raetz EA, Carroll WL: Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia. Paediatr Drugs; 2007;9(3):149-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia.
  • Childhood acute lymphoblastic leukemia (ALL) is a heterogeneous disease.
  • Current treatment approaches are tailored according to the clinical features of the host, genotypic features of the leukemic blast, and early response to therapy.
  • Further insights into the biologic basis of the disease may contribute to novel, rational treatment strategies.
  • Identification of patients who are predicted to have an unfavorable outcome may allow for early intervention such as intensification of therapy or avoidance of drugs that are associated with specific secondary effects such as therapy-related acute myelogenous leukemia.
  • These newer methods of genome analyses complemented by studies involving the proteome as well as host polymorphisms will have a profound impact on the diagnosis and management of childhood ALL.
  • [MeSH-major] Gene Expression Profiling. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma


68. Löwenberg B: Acute myeloid leukemia: the challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program; 2008;:1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia: the challenge of capturing disease variety.
  • The difference between success and failure of treatment of acute myeloid leukemia (AML) is largely determined by genotypic leukemia-specific differences among patients.
  • The diversity of AML genotypes result from somatic genetic alterations settling down in succession in an individual's leukemia clone during the development of the disease.
  • Gene mutations, gene expression abnormalities and other molecular alterations (e.g., microRNA variations) affect critical functions in AML cells, and may exert profound effects on the therapeutic response and outcome of the disease.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074046.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Genetic Markers; 0 / MECOM protein, human; 0 / MicroRNAs; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Transcription Factors
  • [Number-of-references] 80
  •  go-up   go-down


69. Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S, Moritz T, Laws HJ, Hanenberg H, Goebel U, Janka-Schaub GE, Mahotka C, Dilloo D: Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica; 2007 Aug;92(8):1043-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia.
  • BACKGROUND AND OBJECTIVES: Impaired apoptosis, mediated by members of the inhibitor of apoptosis proteins (IAP) family such as survivin, is thought to contribute to leukemic cell survival.
  • Overexpression of survivin was found to correlate with poor prognosis in a variety of cancers including hematologic malignancies.
  • To date, however, there is no information available on the prognostic role of survivin in pediatric precursor B-cell acute lymphocytic leukemia (BCP-ALL), the most frequent malignancy in childhood.
  • DESIGN AND METHODS: In a retrospective study including 66 pediatric patients we analyzed the impact of survivin protein levels on outcome in BCP-ALL.
  • RESULTS: Survivin overexpression, with an up to ten-fold increase of the normal level, was detected in 65% of the leukemic samples in contrast to negligible expression in non-malignant hematopoietic cells.
  • However, patients suffering relapse of disease or death had significantly higher survivin expression than those with a favorable outcome.
  • Overexpression of survivin is a significant prognostic marker for 3 year relapse free, event-free and overall survival, again independent of the established prognostic factors in ALL, such as age and leukocyte count at diagnosis as assessed in multivariate analysis.
  • [MeSH-major] Inhibitor of Apoptosis Proteins / analysis. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Apoptosis. Bone Marrow / pathology. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Female. Gene Expression Regulation, Leukemic. Humans. Infant. Kaplan-Meier Estimate. Male. Neoplastic Stem Cells / pathology. Prognosis. Retrospective Studies. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640858.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


70. Drake AL, Walling HW: Variations in presentation of squamous cell carcinoma in situ (Bowen's disease) in immunocompromised patients. J Am Acad Dermatol; 2008 Jul;59(1):68-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variations in presentation of squamous cell carcinoma in situ (Bowen's disease) in immunocompromised patients.
  • BACKGROUND: Although cutaneous malignancy is well known to occur at a higher rate in organ transplant recipients, limited data exist regarding the presentation of squamous cell carcinoma (SCC) in situ in patients with immunosuppression from any cause.
  • METHODS: A retrospective comparative university-based study, reviewing charts with histologically confirmed Bowen's disease diagnosed between January 1999 and January 2003.
  • Fifty-seven patients (19%) were immunocompromised, including 43 organ transplant recipients, 7 patients with acute and chronic leukemia, and 6 patients with immune-suppressing infections or autoimmune disease.
  • Immunocompromised patients were significantly younger (mean, 61.7 years) than non-immunocompromised patients, 72.6 years, P < .0001) and were more often male (P = .0115).
  • Immunocompromised patients were also more likely to present with tumors on the trunk and extremities (odds ratio [OR], 2.03; P = .0019) and particularly on the neck (OR 3.7; P = .00075) than were non-immunocompromised patients.
  • The rate of recurrence was higher in immunocompromised (9%) than in non-immunocompromised patients (3%; P = .039).
  • [MeSH-major] Bowen's Disease / diagnosis. Bowen's Disease / immunology. Carcinoma in Situ / diagnosis. Carcinoma in Situ / immunology. Immunocompromised Host / immunology. Skin Neoplasms / diagnosis. Skin Neoplasms / immunology


71. Karp JE, Blackford A, Smith BD, Alino K, Seung AH, Bolaños-Meade J, Greer JM, Carraway HE, Gore SD, Jones RJ, Levis MJ, McDevitt MA, Doyle LA, Wright JJ: Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res; 2010 Jul;34(7):877-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
  • In a Phase II study, flavopiridol 50 mg/m(2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 g/m(2)/72 h ara-C beginning day 6 and 40 mg/m(2) mitoxantrone on day 9 (FLAM) to 45 adults with newly diagnosed acute myelogenous leukemia (AML) with multiple poor-risk features.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. Allopurinol .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1235-48 [19776405.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4063-73 [19144992.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1249-59 [19776406.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):376-87 [10699068.001]
  • [Cites] Cell Death Differ. 2001 Jul;8(7):715-24 [11464216.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):31793-9 [11431468.001]
  • [Cites] Genome Biol. 2001;2(10):RESEARCH0041 [11597333.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3527-38 [12429644.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Leuk Res. 2003 Apr;27(4):313-21 [12531222.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):307-15 [12538483.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1822-33 [12702569.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Am J Med. 1969 Sep;47(3):351-66 [5258033.001]
  • [Cites] Ann Intern Med. 1975 Jan;82(1):54-7 [16553.001]
  • [Cites] Medicine (Baltimore). 1980 Nov;59(6):409-25 [7003298.001]
  • [Cites] Blood. 1989 Oct;74(5):1499-506 [2676014.001]
  • [Cites] Biochem Pharmacol. 1993 Nov 17;46(10):1831-40 [8250970.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):2973-8 [8674031.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):4856-61 [8895733.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3375-80 [9269999.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4634-41 [10493518.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8403-12 [16322302.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):138-48 [16432172.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • [Cites] Leuk Lymphoma. 2006 Apr;47(4):697-706 [16690529.001]
  • [Cites] Blood. 2007 Jan 15;109(2):399-404 [17003373.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1810-6 [17095617.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1908-15 [17488990.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4467-73 [17671131.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2637-45 [18981292.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4052-62 [19144991.001]
  • [CommentIn] Leuk Res. 2010 Jul;34(7):856-7 [20378170.001]
  • (PMID = 19962759.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P30 CA06973-44; United States / NCI NIH HHS / CA / U01 CA069854; United States / NCRR NIH HHS / RR / M01-RR0052; United States / NCI NIH HHS / CA / U01 CA70095; United States / NCI NIH HHS / CA / CA069854-05; United States / NCI NIH HHS / CA / U01 CA070095; United States / NCRR NIH HHS / RR / M01 RR000052; United States / NCI NIH HHS / CA / U01 CA069854-05
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Piperidines; 0 / Polyamines; 04079A1RDZ / Cytarabine; 45AD6X575G / alvocidib; 63CZ7GJN5I / Allopurinol; 9YCX42I8IU / Sevelamer; BZ114NVM5P / Mitoxantrone
  • [Other-IDs] NLM/ NIHMS158765; NLM/ PMC2875369
  •  go-up   go-down


72. Buitrón-Santiago N, Arteaga-Ortiz L, Rosas-López A, Aguayo A, López-Karpovitch X, Crespo-Solís E: [Acute myeloid leukemia in adults: experience at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán from 2003 to 2008]. Rev Invest Clin; 2010 Mar-Apr;62(2):100-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute myeloid leukemia in adults: experience at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán from 2003 to 2008].
  • [Transliterated title] Experiencia del INCMNSZ en pacientes adultos con leucemia mieloide aguda. Cohorte 2003-2008.
  • INTRODUCTION: Acute myeloid leukemia (AML) comprises a group of diseases with different biologic characteristics; despite knowledge improvements, these are not reflected in long term survival.
  • Between January 2003 and July 2008, patients with AML diagnosis were included (except promyelocitic).
  • At diagnosis: tumor lysis syndrome in 4/ 53 (7.5%), 3/51 (5.9%) with altered liver function test and hyperleukocytosis in 8/53 (15.1%).
  • There were 2 losses during follow up, 7 patients did not receive chemotherapy with curative intent and 1 died at diagnosis.
  • Median disease free survival (DFS) was 491 days (366-615), with a median follow up of 993 days (105-1744).
  • CONCLUSIONS: Long term survival in AML patients remains poor despite improvements in diagnosis, classification, and treatment.
  • In our institution, it is required to improve induction protocols and cytogenetic analysis in order to adequately choose the group of patients that could be benefit from stem cell transplant.
  • [MeSH-major] Leukemia, Myeloid, Acute

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20597388.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


73. Aydin-Sayitoglu M, Hatirnaz O, Erensoy N, Ozbek U: Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias. Am J Hematol; 2006 Mar;81(3):162-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias.
  • Acute leukemias (ALs) are heterogeneous diseases.
  • Functional polymorphisms in the genes encoding detoxification enzymes cause inter-individual differences, which contribute to leukemia susceptibility.
  • The CYP2D6*3 variant allele frequency was lower in the overall acute leukemia patients (0.6%) compared to controls (P = 0.03).
  • No association was found for the studied CYP2D6*4, CYP1A1*2A, and GSTT1"null" variants and the risk of acute leuke-mia (ALL or AML).
  • This case-control study suggests a contribution of CYP2E1, CYP2D6, and GSTM1 "null" variants to the development of acute leukemias.
  • [MeSH-major] Cytochrome P-450 CYP1A1 / genetics. Cytochrome P-450 CYP2D6 / genetics. Cytochrome P-450 CYP2E1 / genetics. Genetic Predisposition to Disease. Glutathione Transferase / genetics. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16493615.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.14.13.- / Cytochrome P-450 CYP2E1; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.14.14.1 / Cytochrome P-450 CYP2D6; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


74. Xu LP, Huang XJ, Liu KY, Chen H, Liu DH, Zhang YC, Chen YH, Han W, Gao ZY, Lu DP: [Allogeneic hematopoietic stem cell transplantation for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia]. Beijing Da Xue Xue Bao; 2005 Jun 18;37(3):231-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allogeneic hematopoietic stem cell transplantation for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia].
  • OBJECTIVE: To explore the optimal time of allogeneic hematopoietic stem cell transplantation (allo-HSCT) applied in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and the optimum order of donor selection.
  • The Kaplan-Meier method was used to estimate the probabilities of leukemia-free survival (LFS), overall survival (OS) and relapse incidence (RI), and the factors were compared by means of the Log-rank test.
  • In univariate prognostic analysis model, the OS was higher in CR1 group pre-HSCT than that in non-CR1 group (74.50% vs 22.22%, P=0.0046), LFS was higher (49.06% vs 11.11%, P=0.0057), RI was lower (44.80% vs 84.76%, P=0.0157); the OS was higher in M(BCR/ABL) group than that in m(BCR/ABL) group (100% vs 40.91%, P=0.0318), LFS was higher (75% vs 17.72%, P=0.0057), RI was lower (25% vs 77.88, P=0.0116); OS was similar in HLA MM RD group to that in HLA identical group (52.65% vs 55.56%, P=0.6247), LFS was similar (45.12% vs 30.00%, P=0.8315), and RI was also similar (50.77% vs 60.62%, P=0.8217).
  • In multiple covariate analysis model, the BCR/ABL type was the risk factor of LFS [P=0.005, Exp(B)=9.971] and RI (P=0.006, Exp(B)=9.488), the status of disease pre-HSCT and BCR/ABL subtype was the risk factor of OS [P was 0.010 and 0.038, Exp(B) was 4.532 and 37.537 respectively].
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


75. Matsunaga T, Fukai F, Miura S, Nakane Y, Owaki T, Kodama H, Tanaka M, Nagaya T, Takimoto R, Takayama T, Niitsu Y: Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia; 2008 Feb;22(2):353-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia.
  • We investigated whether FNIII14, a 22-mer peptide derived from fibronectin (FN) that potently impairs interaction of FN with beta1-integrin, could overcome cell adhesion-mediated drug resistance (CAM-DR) induced by very late antigen (VLA)-4-to-FN interaction in acute myelogenous leukemia (AML).
  • Two AML cell lines, U937 cells and HL-60 cells, and fresh leukemic cells from six AML patients with high alpha4-integrin expression exhibited CAM-DR to cytosine arabinoside (Ara C) through VLA-4-to-FN interaction, while fresh leukemic cells from two AML patients with low alpha4-integrin expression did not display CAM-DR to Ara C.
  • In a mouse model of minimal residual disease (MRD) in bone marrow, 100% survival was achieved by combining FNIII14 with Ara C, whereas Ara C alone prolonged survival only slightly.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Resistance / drug effects. Fibronectins / pharmacology. Leukemia, Myeloid, Acute / drug therapy. Neoplasm, Residual / drug therapy. Peptide Fragments / pharmacology
  • [MeSH-minor] Animals. Antigens, CD29. Bone Marrow / pathology. Cell Adhesion / drug effects. Cell Line, Tumor. Cytarabine / pharmacology. Cytarabine / therapeutic use. Drug Therapy, Combination. Humans. Mice. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors. Tumor Cells, Cultured


76. Karimi M, Eshghi P: Unusual lymphoblastic leukemia/lymphoma in Eastern Iran. Indian J Pediatr; 2006 Jul;73(7):619-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual lymphoblastic leukemia/lymphoma in Eastern Iran.
  • Lymphoblastic lymphoma-leukemia (LBLL) most commonly presents with mediastinal masses (50-75%), while pleural and pericardial effusion may also be present.
  • Lymphadenopathy usually in the neck, axilla or supraclavicular regions, is considered as another typical presentation of the disease.
  • This is a case report of a six-year-old boy with unusual huge enlargement of maxilla, mandible and soft palate as well as gingival hypertrophy which led to secondary respiratory and feeding difficulties.
  • Morphologic and flowcytometric evaluation of bone marrow aspiration showed that it was a T cell type acute leukemia which may be due to dissemination of a lymphoblastic lymphoma and considered as a case of lymphoma-leukemia.
  • [MeSH-major] Gingival Hypertrophy / etiology. Jaw Diseases / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Child. Humans. Iran. Leukemia, Lymphoid / complications. Leukemia, Lymphoid / diagnosis. Male

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1991 Dec 1;78(11):2814-22 [1835410.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Blood. 1986 Feb;67(2):474-8 [3080041.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 1984 Jul;64(1):38-47 [6375764.001]
  • [Cites] Cancer. 1976 Aug;38(2):964-83 [1067894.001]
  • [Cites] Ann Intern Med. 1978 Sep;89(3):415-7 [356693.001]
  • [Cites] Mod Pathol. 1988 Jan;1(1):15-22 [3266334.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Oct;82(4):434-6 [8899783.001]
  • [Cites] Cancer Res. 1983 Sep;43(9):4486-90 [6191861.001]
  • [Cites] J Am Acad Dermatol. 1991 Dec;25(6 Pt 1):1023-31 [1810981.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1993 Jul;29B(3):225-9 [8298427.001]
  • [Cites] Br J Haematol. 1996 Mar;92(3):665-72 [8616033.001]
  • (PMID = 16877858.001).
  • [ISSN] 0973-7693
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


77. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G: Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A; 2010 Apr 20;107(16):7473-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A phase II clinical trial with single-agent decitabine was conducted in older patients (>or=60 years) with previously untreated acute myeloid leukemia (AML) who were not candidates for or who refused intensive chemotherapy.
  • Nineteen (36%) had antecedent hematologic disorder or therapy-related AML; 16 had complex karyotypes (>or=3 abnormalities).
  • Nine additional subjects had no morphologic evidence of disease with incomplete count recovery, for an overall response rate of 64% (n = 34).
  • Median overall and disease-free survival durations were 55 and 46 weeks, respectively.
  • [MeSH-major] Azacitidine / analogs & derivatives. Leukemia, Myeloid, Acute / metabolism. MicroRNAs / biosynthesis
  • [MeSH-minor] Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Cohort Studies. DNA Methylation. Disease-Free Survival. Female. Humans. Karyotyping. Male. Middle Aged. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2009 Jun;145(5):598-605 [19344426.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2867-8 [19299654.001]
  • [Cites] Blood. 2009 Aug 6;114(6):1166-73 [19470696.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3842-8 [19528372.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1235-48 [19776405.001]
  • [Cites] Br J Haematol. 2010 Jan;148(1):48-58 [19821823.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):556-61 [20026803.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):562-9 [20026804.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):549-55 [20026805.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2429-40 [12011120.001]
  • [Cites] Leukemia. 2003 Feb;17(2):350-8 [12592335.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1635-40 [14604977.001]
  • [Cites] Blood. 1987 Aug;70(2):412-7 [3607279.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):103-7 [9916800.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1277-84 [15735013.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1794-803 [16532500.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6361-9 [16778214.001]
  • [Cites] Blood. 2006 Jul 1;108(1):63-73 [16522815.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3271-9 [16882711.001]
  • [Cites] Blood. 2007 Jan 1;109(1):52-7 [16882708.001]
  • [Cites] Br J Haematol. 2007 Feb;136(4):624-7 [17223919.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1114-24 [17315155.001]
  • [Cites] Blood. 2007 Aug 1;110(3):1080-2; author reply 1083 [17644749.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3884-91 [17679729.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15805-10 [17890317.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1638-45 [18565853.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):223-32 [19230772.001]
  • [Cites] Blood. 2009 Jun 18;113(25):6411-8 [19211935.001]
  • (PMID = 20368434.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00492401
  • [Grant] United States / NCI NIH HHS / CA / P50 CA140158; United States / NCI NIH HHS / CA / R01 CA102031; United States / NCI NIH HHS / CA / K23 CA120708; United States / NCI NIH HHS / CA / K12CA133250; United States / NCI NIH HHS / CA / K23CA120708; United States / NCI NIH HHS / CA / K12 CA133250; United States / NCI NIH HHS / CA / N01CM62207; United States / NCI NIH HHS / CM / N01-CM-62207
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / MIRN29 microRNA, human; 0 / MicroRNAs; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC2867720
  •  go-up   go-down


78. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S, Pascutto C, Lazzarino M, Cazzola M: A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia; 2010 Sep;24(9):1574-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.
  • We studied the relationship between JAK2 (V617F) mutant allele burden and clinical phenotype, disease progression and survival in patients with polycythemia vera (PV).
  • Direct relationships were found between mutant allele burden and hemoglobin concentration (P=0.001), white blood cell count (P=0.001), spleen size (P=0.001) and age-adjusted bone marrow cellularity (P=0.002), while an inverse relationship was found with platelet count (P<0.001).
  • During the study period, eight patients progressed to post-PV myelofibrosis (MF) (all carrying >50% mutant alleles), while 10 patients developed acute myeloid leukemia (AML).
  • Leukocytosis did not affect thrombosis, MF, leukemia or survival.
  • [MeSH-major] Alleles. Cell Transformation, Neoplastic / genetics. Janus Kinase 2 / genetics. Leukemia / genetics. Leukocytosis / genetics. Polycythemia Vera / genetics. Primary Myelofibrosis / genetics. Vascular Diseases / complications


79. Sevilla J, Fernández-Plaza S, Lassaletta A, González-Vicent M, Contra T, Madero L: Early acute myeloblastic leukemia treatment for childhood myelodysplastic syndrome with t(3;5) (NPM/MLF1). J Pediatr Hematol Oncol; 2007 Dec;29(12):839-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early acute myeloblastic leukemia treatment for childhood myelodysplastic syndrome with t(3;5) (NPM/MLF1).
  • Here in we described a 2-year-old child diagnosed with the disease, without a suitable hematopoietic donor, treated early in the disease with chemotherapy.
  • This unusual MDS needs further studies to better understand the disease.
  • [MeSH-major] Chromosomes, Human, Pair 3. Chromosomes, Human, Pair 5. Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18090933.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / NPM-MLF1 protein, human; 0 / Oncogene Proteins, Fusion; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FTK8U1GZNX / Thioguanine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; BFM 78 protocol
  •  go-up   go-down


80. Giovannetti E, Ugrasena DG, Supriyadi E, Vroling L, Azzarello A, de Lange D, Peters GJ, Veerman AJ, Cloos J: Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia. Leuk Res; 2008 Jan;32(1):19-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia.
  • We studied these polymorphisms in children with acute lymphoblastic leukaemia (ALL) and in subjects without malignancy in Indonesia and Holland.
  • [MeSH-major] Genetic Predisposition to Disease. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Thymidylate Synthase / genetics

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17395259.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.1.45 / Thymidylate Synthase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


81. Benesch M, Sovinz P, Lackner H, Schwinger W, Dornbusch HJ, Urban C: Five-month marrow aplasia in a child with refractory acute myeloid leukemia: successful management with continuous granulocyte support and reduced-intensity conditioning followed by matched unrelated bone marrow transplantation. J Pediatr Hematol Oncol; 2005 Apr;27(4):236-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five-month marrow aplasia in a child with refractory acute myeloid leukemia: successful management with continuous granulocyte support and reduced-intensity conditioning followed by matched unrelated bone marrow transplantation.
  • A 10-year-old girl diagnosed with acute myeloid leukemia FAB M4 failed to achieve remission following several courses of induction chemotherapy.
  • After reinduction and reduced-intensity conditioning including fludarabine, Campath-1H, and melphalan, the patient received unmanipulated marrow from an HLA-matched unrelated donor.
  • Graft-versus-host disease did not occur.
  • [MeSH-major] Anemia, Aplastic / etiology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Graft vs Host Disease / prevention & control. Leukemia, Myelomonocytic, Acute / therapy. Neoplasm Recurrence, Local / therapy. Transplantation Conditioning. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838401.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


82. Yue LJ, Chen XW, Li CR, Li CG, Shi HS, Zhang M: [Single-nucleotide polymorphisms of the cytidine deaminase gene in childhood with acute leukemia and normal Chinese children]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Dec;24(6):699-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Single-nucleotide polymorphisms of the cytidine deaminase gene in childhood with acute leukemia and normal Chinese children].
  • OBJECTIVE: Cytidine deaminase (CDA) is a key enzyme for metabolizing chemotherapeutic agent cytosine arabinoside (Ara-C), a deoxycytidine analog used for treatment of acute leukemia and lymphomas.
  • METHODS: The bone marrow samples from 87 childhood patients with acute leukemia and peripheral blood samples from 199 non-malignancy-bearing children were obtained to prepare complementary DNAs (cDNAs).
  • The distributive difference of each genotype was evaluated between children with acute leukemia and control children.
  • No association with susceptibility to disease was observed.
  • [MeSH-major] Cytidine Deaminase / genetics. Leukemia / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Acute Disease. Asian Continental Ancestry Group / genetics. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067088.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


83. Wiseman DH, Hunter HJ, Dennis M: Bullous pyoderma gangrenosum in acute myeloid leukaemia. Eur J Haematol; 2007 Jul;79(1):91-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bullous pyoderma gangrenosum in acute myeloid leukaemia.
  • [MeSH-major] Leukemia, Myeloid / complications. Pyoderma Gangrenosum / complications
  • [MeSH-minor] Acute Disease. Aged. Humans. Male. Prednisone / therapeutic use

  • Genetic Alliance. consumer health - Pyoderma gangrenosum.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419746.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] VB0R961HZT / Prednisone
  •  go-up   go-down


84. Green C, Linch DC, Gale RE: Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcome. Br J Haematol; 2008 Jul;142(3):423-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcome.
  • FLT3 internal tandem duplication mutant levels >50%, indicative of bi-allelic disease in some cells, are associated with a particularly poor prognosis in acute myeloid leukaemia; lower levels have an intermediate prognosis relative to wild-type FLT3.
  • To examine whether a small population of homozygous mutant cells is responsible for the worse relapse risk rather than heterozygous disease per se, we determined the genetic composition of 34 intermediate mutant level (25-50%) samples.
  • Bi-allelic disease in intermediate mutant level cases is uncommon and heterozygous disease is sufficient for adverse outcome.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Tandem Repeat Sequences. fms-Like Tyrosine Kinase 3 / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537976.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


85. Bianco M, Turner J, Rosenthal N: Increased blasts mimicking acute leukemia in a patient with polysubstance abuse. Arch Pathol Lab Med; 2005 Feb;129(2):e35-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased blasts mimicking acute leukemia in a patient with polysubstance abuse.
  • Distinguishing these changes from an acute leukemic process can be difficult.
  • In particular, the diagnosis of hypocellular bone marrow with increased blasts, also known as hypocellular or hypoplastic acute leukemia, presents a diagnostic dilemma for pathologists.
  • Recovery of peripheral blood cell counts and reticulocytosis occurred with withdrawal of the offending agents, and he remains alive and well 1 year later.
  • [MeSH-major] Leukemia / diagnosis. Lymphocytes / metabolism. Substance-Related Disorders / diagnosis
  • [MeSH-minor] Acute Disease. Diagnosis, Differential. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15679445.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Dvorak CC, Agarwal R, Dahl GV, Gregory JJ, Feusner JH: Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia. Biol Blood Marrow Transplant; 2008 Jul;14(7):824-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia.
  • The optimal form of treatment for children with relapsed or refractory acute promyelocytic leukemia (APL) is unclear.
  • We retrospectively analyzed the results of 32 (11 autologous, 21 allogeneic) hematopoietic stem cell transplants (HSCT) performed for children originally treated on either the Eastern Cooperative Group E2491 Trial or the Cancer and Leukemia Group B C9710 Trial and subsequently diagnosed with relapsed or refractory APL.

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Jun;14(6):1006-13 [10865965.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4298-302 [12393590.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1578-82 [12738663.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Sep;16(3):483-94 [12935964.001]
  • [Cites] Leukemia. 2003 Oct;17(10):1930-3 [14513040.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4377-85 [14645428.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1404-12 [15084614.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):484-6 [14730393.001]
  • [Cites] Bone Marrow Transplant. 2004 Nov;34(9):795-8 [15354207.001]
  • [Cites] Bone Marrow Transplant. 2004 Nov;34(9):799-806 [15361903.001]
  • [Cites] Blood. 1993 Mar 1;81(5):1369-75 [8095167.001]
  • [Cites] Bone Marrow Transplant. 1996 Nov;18 Suppl 2:59-62 [8932801.001]
  • [Cites] Bone Marrow Transplant. 1997 Apr;19(7):679-83 [9156244.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1321-5 [9242568.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):559-62 [9827935.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):120-6 [15534358.001]
  • [Cites] Bone Marrow Transplant. 2005 Jul;36(1):83-4 [15880128.001]
  • [Cites] Blood. 2005 Jul 15;106(2):447-53 [15677559.001]
  • [Cites] Leuk Lymphoma. 2005 Jul;46(7):1007-16 [16019551.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7632-40 [16234524.001]
  • [Cites] Bone Marrow Transplant. 2006 Apr;37(8):785-6 [16501592.001]
  • [Cites] Pediatr Blood Cancer. 2007 May;48(5):582-5 [16123994.001]
  • [Cites] Bone Marrow Transplant. 2007 Apr;39(8):461-9 [17322930.001]
  • [Cites] Ann Hematol. 2001 Jul;80(7):417-22 [11529468.001]
  • [Cites] Leukemia. 2001 Nov;15(11):1696-700 [11681409.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1247-53 [10942364.001]
  • (PMID = 18541203.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; None / None / / U10 CA098543-06; United States / NCI NIH HHS / CA / U10 CA098543-06
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS162635; NLM/ PMC2796449
  •  go-up   go-down


87. Marks R, Finke J: [The impact of stem cell therapy in hematology and oncology]. Internist (Berl); 2006 May;47(5):467-8, 470-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The impact of stem cell therapy in hematology and oncology].
  • Allogeneic HSCT results in cure from acute leukemia with unfavorable prognosis in a high percentage of patients.
  • Recent developments target the expansion of the donor pool for allogeneic stem cells and want to reduce chemotherapeutic toxicity of allogeneic transplantation with sustained anti-leukemia efficacy.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Bone Marrow Purging. Combined Modality Therapy. Graft vs Host Disease / immunology. Graft vs Host Disease / prevention & control. Graft vs Leukemia Effect / immunology. Hematopoietic Stem Cells / immunology. Humans. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / therapy. Prognosis. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Nov 15;104(10):3028-37 [15256423.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1287-95 [15044639.001]
  • [Cites] N Engl J Med. 1995 Jan 26;332(4):217-23 [7808487.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3918-27 [14517188.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Jul;9(7):472-81 [12869961.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2273-83 [15111618.001]
  • [Cites] Tissue Antigens. 2003 Jun;61(6):415-24 [12823765.001]
  • [Cites] Blood. 2004 Feb 1;103(3):767-76 [12958064.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2677-84 [15591112.001]
  • [Cites] Ann Hematol. 2001 Jul;80(7):398-405 [11529465.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1254-8 [10942365.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5074-87 [16051954.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1480-4 [12697870.001]
  • [Cites] Lancet. 2002 Jun 15;359(9323):2065-71 [12086759.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2667-74 [15238420.001]
  • [Cites] N Engl J Med. 1998 Oct 22;339(17):1186-93 [9780338.001]
  • [Cites] Blood. 1991 Oct 15;78(8):2120-30 [1912589.001]
  • [Cites] N Engl J Med. 2000 Sep 14;343(11):750-8 [10984562.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1147-55 [15039204.001]
  • [Cites] N Engl J Med. 1981 Jun 18;304(25):1529-33 [7015133.001]
  • [Cites] Ann Oncol. 2003 May;14(5):737-44 [12702528.001]
  • [Cites] Lancet. 1996 Feb 10;347(8998):353-7 [8598700.001]
  • [Cites] Ann Intern Med. 1991 Jul 1;115(1):13-8 [2048858.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2495-502 [14695409.001]
  • [Cites] Blood. 2005 May 15;105(10):4147-8 [15867422.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2304-12 [16193083.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Ann Intern Med. 1994 Apr 15;120(8):646-52 [8135448.001]
  • [Cites] N Engl J Med. 1996 Jul 11;335(2):91-7 [8649495.001]
  • [Cites] Lancet. 2005 Dec 3;366(9501):1935-44 [16325695.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(7):575-90 [16086045.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):209-16 [11360893.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7(5):294-301 [11400952.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(6):597-603 [11128809.001]
  • (PMID = 16557411.001).
  • [ISSN] 0020-9554
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


88. Tabata M, Kai S, Satake A, Wakae T, Toda A, Chin M, Nishioka K, Tanaka H, Itsukuma T, Yamaguchi M, Okada M, Takatsuka H, Misawa M, Hara H: Relationships between hematological recovery and overall survival in older adults undergoing allogeneic bone marrow transplantation. Intern Med; 2005 Jan;44(1):35-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The advancement of hematopoietic stem cell transplantation techniques and the increase in frequency of hematological malignancy in older patients are expected to expand the indications to include more elderly patients.
  • There were 8 cases of acute myelogenous leukemia (AML), 5 cases of acute lymphocytic leukemia (ALL), 6 cases of chronic myelogenous leukemia (CML) and 2 cases of myelodysplastic syndrome (MDS).
  • We did not observe any severe graft-versus-host disease (GVHD) or regimen-related toxicities.
  • [MeSH-minor] Adult. Cause of Death. Female. Graft vs Host Disease / mortality. Humans. Leukocyte Count. Male. Middle Aged. Neutrophils. Platelet Count. Retrospective Studies


89. Jiang H, Liu KY, Tong CR, Jiang B, Lu DP: [The efficacy of chemotherapy in combination with auto-cytokine-induced killer cells in acute leukemia]. Zhonghua Nei Ke Za Zhi; 2005 Mar;44(3):198-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The efficacy of chemotherapy in combination with auto-cytokine-induced killer cells in acute leukemia].
  • OBJECTIVE: To evaluate the efficacy of chemotherapy in combination with autologous cytokine induced killer cells for the treatment of acute leukemia.
  • METHODS: 41 patients with acute leukemia were evaluated; complete remission was achieved in these patients for more than 6 months duration after chemotherapy.
  • Preparation of CIK cells was as follows: Peripheral blood mononuclear cells from the patient were collected by using blood cell separator, then cultured in the medium containing monoclonal antibody against CD(3), interleukin-2 and interferon gamma for about 10 days, and finally infused back to the patient on the first day after chemotherapy.
  • CONCLUSIONS: CCR rate was higher in patients with chemotherapy plus CIK cells for acute leukemia than in patients with chemotherapy alone.
  • [MeSH-major] Cytokines / pharmacology. Immunotherapy, Adoptive. Killer Cells, Natural / immunology. Leukemia / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Remission Induction

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15840260.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


90. Récher C, Dos Santos C, Demur C, Payrastre B: mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle; 2005 Nov;4(11):1540-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mTOR, a new therapeutic target in acute myeloid leukemia.
  • The mTOR (mammalian target of rapamycin) serine threonine kinase is involved in the regulation of the cell cycle, apoptosis and angiogenesis. mTOR inhibitors (rapamycin, or analogues such as CCI-779, RAD001, AP23573), which have been shown to have a potent anti-neoplastic effect in many solid tumor models, are now being used in clinical trials.
  • Recent data have shown that the mTOR pathway is also aberrantly activated in hematological malignancies including acute myeloid leukemia (AML).
  • This disease still has a bad prognosis and new therapeutic strategies are required.
  • Rapamycin, used at low concentrations, induces the profound inhibition of AML cell clonogenic properties in 60% of cases while sparing their normal counterparts.
  • In this review, we discuss the possible mechanisms of mTOR activation, the mechanisms involved in the inhibition of cell proliferation by rapamycin, the possible resistance mechanisms and ways of improving rapamycin efficacy in the context of AML.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Delivery Systems / methods. Growth Inhibitors / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / enzymology. Protein Kinase Inhibitors / therapeutic use. Protein Kinases / metabolism
  • [MeSH-minor] Animals. Disease Models, Animal. Humans. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Protein-Serine-Threonine Kinases / physiology. TOR Serine-Threonine Kinases

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16205124.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Growth Inhibitors; 0 / Protein Kinase Inhibitors; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Number-of-references] 169
  •  go-up   go-down


91. Estey E, Döhner H: Acute myeloid leukaemia. Lancet; 2006 Nov 25;368(9550):1894-907
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukaemia.
  • Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haemopoietic progenitor cells and the most common malignant myeloid disorder in adults.
  • In the past few years, research in molecular biology has been instrumental in deciphering the pathogenesis of the disease.
  • This difference is related to comorbidities associated with ageing and to disease biology.
  • [MeSH-major] Leukemia, Myeloid. Stem Cell Transplantation

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet. 2007 Feb 3;369(9559):367 [17276770.001]
  • (PMID = 17126723.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 178
  •  go-up   go-down


92. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL: Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol; 2007 Feb 10;25(5):493-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
  • PURPOSE: Pediatric Oncology Group (POG) studies 9426 and 9425 evaluated dexrazoxane (DRZ) as a cardiopulmonary protectant during treatment for Hodgkin's disease (HD).
  • We evaluated incidence and risk factors of acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) and second malignant neoplasms (SMNs).
  • With median 58 months' follow-up, 4-year cumulative incidence rate (CIR) for AML/MDS was 2.55% +/- 1.0% with DRZ versus 0.85% +/- 0.6% in the non-DRZ group (P = .160).
  • For any SMN, the CIR for DRZ was 3.43% +/- 1.2% versus CIR for non-DRZ of 0.85% +/- 0.6% (P = .060).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Chelating Agents / adverse effects. Hodgkin Disease / drug therapy. Leukemia, Myeloid / chemically induced. Myelodysplastic Syndromes / chemically induced. Neoplasms, Second Primary / chemically induced. Razoxane / adverse effects
  • [MeSH-minor] Acute Disease. Adolescent. Cohort Studies. Enzyme Inhibitors / adverse effects. Female. Follow-Up Studies. Heart Diseases / chemically induced. Heart Diseases / prevention & control. Humans. Incidence. Lung Diseases / chemically induced. Lung Diseases / prevention & control. Male. Neoplasm Staging. Osteosarcoma / chemically induced. Risk Assessment. Risk Factors. Thyroid Neoplasms / chemically induced. Time Factors. Topoisomerase II Inhibitors


93. Mikesch JH, Steffen B, Berdel WE, Serve H, Müller-Tidow C: The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. Leukemia; 2007 Aug;21(8):1638-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia.
  • Wnt signaling plays an important role in stem cell self-renewal and proliferation.
  • Aberrant activation of Wnt signaling and downstream effectors has been demonstrated in acute myeloid leukemia.
  • Here, mutant receptor tyrosine kinases, such as Flt3 and chimeric transcription factors such as promyelocytic leukemia-retinoic acid receptor-alpha and acute myeloid leukemia1-ETO, induce downstream Wnt signaling events.
  • [MeSH-major] Leukemia, Myeloid / etiology. Signal Transduction / physiology. Wnt Proteins / physiology
  • [MeSH-minor] Acute Disease. Humans

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17554387.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Wnt Proteins
  • [Number-of-references] 155
  •  go-up   go-down


94. Toubai T, Tanaka J, Ota S, Fukuhara T, Hashino S, Kondo T, Kasai M, Kakinoki Y, Masauzi N, Morioka M, Kawamura T, Iwasaki H, Asaka M, Imamura M: Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients. Am J Hematol; 2005 Nov;80(3):181-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients.
  • We evaluate whether molecular monitoring of minimal residual disease (MRD) using TCR delta (TCRD), TCR gamma (TCRG), and immunoglobulin H (IgH) gene rearrangements in the bone marrow (BM) is correlated with clinical events in ALL patients.
  • The median WBC count was 11.3 x 10(9)/L at diagnosis.
  • All patients had L2 type ALL.
  • We analyzed 9 of 11 CR patients who could be examined immediately after induction chemotherapy (including re-induction therapy).
  • Event-free survival (EFS, 0%) and disease-free survival (DFS, 0%) at 1 year in CR patients with MRD level >or=10(-3) (n = 3) were significantly lower than those in CR patients with MRD level <10(-3) (n = 6) (log-rank test, P = 0.013, 0.013).
  • [MeSH-major] Gene Rearrangement. Gene Rearrangement, T-Lymphocyte. Immunoglobulin Heavy Chains / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Clone Cells. Female. Follow-Up Studies. Gene Rearrangement, delta-Chain T-Cell Antigen Receptor. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Male. Middle Aged. Molecular Diagnostic Techniques. Neoplasm, Residual / diagnosis. Remission Induction. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247752.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


95. Chuk MK, McIntyre E, Small D, Brown P: Discordance of MLL-rearranged (MLL-R) infant acute lymphoblastic leukemia in monozygotic twins with spontaneous clearance of preleukemic clone in unaffected twin. Blood; 2009 Jun 25;113(26):6691-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discordance of MLL-rearranged (MLL-R) infant acute lymphoblastic leukemia in monozygotic twins with spontaneous clearance of preleukemic clone in unaffected twin.
  • Concordance of MLL-rearranged acute leukemia in infant monozygotic twins is thought to be 100% with a very short latency period, suggesting that either the MLL fusion itself is sufficient to cause leukemia or that it promotes the rapid acquisition of additional oncogenic events that result in overt disease.
  • Twin A presented at age 9 months with MLL-ENL(+) acute lymphoblastic leukemia and twin B remains healthy 3 years later.
  • The presence and eventual clearance of a clonal population of MLL-ENL(+) cells was shown in the bone marrow and peripheral blood of twin B.
  • Clearance of this clone was temporally associated with viral-induced cytopenias, suggesting an immune-mediated clearance of the clone before the development of leukemia.
  • Thus, concordance of MLL-rearranged acute leukemia in infant monozygotic twins is not universal.
  • [MeSH-major] Myeloid-Lymphoid Leukemia Protein / analysis. Oncogene Proteins, Fusion / analysis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Preleukemia / genetics. Respiratory Tract Infections / immunology. Twins, Monozygotic. Virus Diseases / immunology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Viral Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10984-9 [10995463.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1499-503 [10551495.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8242-7 [12048236.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15101-6 [12415113.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):639-49 [12951583.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Apr;39(4):335-40 [14978794.001]
  • [Cites] Leukemia. 1988 Feb;2(2):120-5 [3278171.001]
  • [Cites] Lancet. 1988 Dec 10;2(8624):1323-7 [2904050.001]
  • [Cites] Nature. 1993 May 27;363(6427):358-60 [8497319.001]
  • [Cites] Blood. 1994 Feb 1;83(3):641-4 [8298125.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] EMBO J. 1999 Jul 1;18(13):3564-74 [10393173.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1057-62 [10419898.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):193-203 [16467884.001]
  • [Cites] Leukemia. 2007 Apr;21(4):633-41 [17268512.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2137-41 [18719616.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2992-6 [11929791.001]
  • (PMID = 19411627.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA111728; United States / NCI NIH HHS / CA / R01 CA090668
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MLL-ENL oncoprotein, human; 0 / MLLT1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  • [Other-IDs] NLM/ PMC2943757
  •  go-up   go-down


96. Zhang SJ, Shi JY, Li JY: GATA-2 L359 V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism. Leuk Res; 2009 Aug;33(8):1141-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic myeloid leukemia (CML) progression is characterized by occurrence of new cytogenetic and molecular abnormalities.
  • Finally, no GATA-2 L359 V mutation was found in 270 acute myeloid leukemia, 30 myelodysplastic syndrome, 50 acute lymphoblastic leukemia, 12 chronic lymphocytic leukemia, 40 CML chronic phase and 286 BCR/ABL negative myeloproliferative disorders except CML blast crisis.
  • [MeSH-major] Amino Acid Substitution. Blast Crisis / genetics. GATA2 Transcription Factor / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Mutation, Missense. Polymorphism, Single Nucleotide
  • [MeSH-minor] DNA Mutational Analysis. Disease Progression. Female. Hematologic Neoplasms / genetics. Hematologic Neoplasms / metabolism. Humans. Male

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304323.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GATA2 Transcription Factor; 0 / GATA2 protein, human
  •  go-up   go-down


97. Nath SV, Westerman D, Campbell LJ, Seymour JF: Clonal "devolution" in a case of essential thrombocythemia with transformation from refractory cytopenia with multilineage dysplasia to acute myeloid leukemia. Leuk Lymphoma; 2006 Jun;47(6):1160-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal "devolution" in a case of essential thrombocythemia with transformation from refractory cytopenia with multilineage dysplasia to acute myeloid leukemia.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / etiology. Thrombocythemia, Essential / diagnosis
  • [MeSH-minor] Aged. Blood Cell Count. Brain Ischemia / complications. Brain Ischemia / pathology. Cell Lineage. Cell Transformation, Neoplastic. Centromere / ultrastructure. Disease Progression. Fatal Outcome. Humans. Karyotyping. Male. Precancerous Conditions


98. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM: A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood; 2008 Sep 01;112(5):1638-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
  • [MeSH-major] Adenine Nucleotides / administration & dosage. Antineoplastic Agents / administration & dosage. Arabinonucleosides / administration & dosage. Cytarabine / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Chromosome Aberrations. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Mutation. Survival Rate. fms-Like Tyrosine Kinase 3 / genetics


99. Falini B, Nicoletti I, Martelli MF, Mecucci C: Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood; 2007 Feb 1;109(3):874-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.
  • NPM1 mutations occur in 50% to 60% of adult acute myeloid leukemia with normal karyotype (AML-NK) and generate NPM mutants that localize aberrantly in the leukemic-cell cytoplasm, hence the term NPM-cytoplasmic positive (NPMc+ AML).
  • NPMc+ AML shows increased frequency in adults and females, wide morphologic spectrum, multilineage involvement, high frequency of FLT3-ITD, CD34 negativity, and a distinct gene-expression profile.
  • Due to their frequency and stability, NPM1 mutations may become a new tool for monitoring minimal residual disease in AML-NK.
  • Future studies should focus on clarifying how NPM mutants promote leukemia, integrating NPMc+ AML in the upcoming World Health Organization leukemia classification, and eventually developing specific antileukemic drugs.
  • [MeSH-major] Leukemia, Myeloid / genetics. Mutation. Nuclear Proteins / genetics
  • [MeSH-minor] Active Transport, Cell Nucleus. Acute Disease. Cytoplasm / chemistry. Humans


100. Fortier JM, Graubert TA: Murine models of human acute myeloid leukemia. Cancer Treat Res; 2010;145:183-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Murine models of human acute myeloid leukemia.
  • A zebrafish model of acute lymphoblastic leukemia has been generated [37] and Drosophila models have shed light on the biology of epithelial tumors ( reviewed in [60]).
  • [MeSH-major] Disease Models, Animal. Leukemia, Myeloid, Acute
  • [MeSH-minor] Animals. Cell Line, Tumor / transplantation. Genetic Predisposition to Disease. Humans. Leukemia, Radiation-Induced / genetics. Leukemia, Radiation-Induced / pathology. Mice. Mice, Inbred NOD. Mice, Inbred Strains. Mice, SCID. Neoplasm Proteins / genetics. Neoplasm Proteins / physiology. Neoplasm Transplantation. Phenotype. Retroviridae / genetics. Species Specificity. Transduction, Genetic. Transgenes. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306252.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 71
  •  go-up   go-down